US20050192542A1 - Method of treatment using electroporation mediated delivery of drugs and genes - Google Patents
Method of treatment using electroporation mediated delivery of drugs and genes Download PDFInfo
- Publication number
- US20050192542A1 US20050192542A1 US10/783,161 US78316104A US2005192542A1 US 20050192542 A1 US20050192542 A1 US 20050192542A1 US 78316104 A US78316104 A US 78316104A US 2005192542 A1 US2005192542 A1 US 2005192542A1
- Authority
- US
- United States
- Prior art keywords
- electrodes
- tissue
- pairs
- molecules
- electrode
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/327—Applying electric currents by contact electrodes alternating or intermittent currents for enhancing the absorption properties of tissue, e.g. by electroporation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M35/00—Means for application of stress for stimulating the growth of microorganisms or the generation of fermentation or metabolic products; Means for electroporation or cell fusion
- C12M35/02—Electrical or electromagnetic means, e.g. for electroporation or for cell fusion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/0502—Skin piercing electrodes
Definitions
- the present invention relates to the treatment of ailments in humans and other mammals, and more particularly, to an improved method and apparatus for the application of controlled electric fields for in vivo delivery of genes and pharmaceutical compounds into live cells of a patient by electroporation.
- genes and other molecules such as pharmacological compounds can be incorporated into live cells through a process known as electroporation.
- the genes or other molecules are mixed with the live cells in a buffer medium and short pulses of high electric fields are applied.
- the cell membranes are transiently made porous and the genes or molecules enter the cells. There they can modify the genome of the cell.
- Electroporation has been recently suggested as one approach to the treatment of certain diseases such as cancer.
- certain diseases such as cancer.
- chemotherapy it is necessary to use a high enough dose of a drug to kill the cancer cells without killing an unacceptable high number of normal cells. If the chemotherapy drug could be inserted directly inside the cancer cells, this objective could be achieved.
- Some of the best anti-cancer drugs, for trample, bleomycin normally cannot penetrate the membranes of certain cancer cells. However, electroporation makes it possible to insert the bleomycin into the cells.
- This treatment is carried out by infusing an anticancer drug directly into the tumor and applying an electric field to the tumor between a pair of electrodes.
- the field strength must be adjusted reasonably accurately so that electroporation of the cells of the tumor occurs without damage, or at least minimal damage, to any normal or healthy cells.
- a system of electrodes for in vivo electroporation wherein the electrodes may be inserted into body cavities.
- a syringe for injecting molecules and macromolecules for electroporation utilizes needles for injection which also function as electrodes. This construction enables the subsurface placement of electrodes. It would be desirable to have an electrode apparatus having electrodes that can be inserted into or adjacent tumors so that predetermined electric fields can be generated in the tissue for electroporation of the cells of the tumor.
- nucleotide sequences up to 630 kb can be introduced into mammalian cells via electroporation (Eanault, et al., Gene ( Amsterdam ), 144(2): 205, 1994; Nucleic Acids Research , 15(3): 1311, 1987; Knutson, et al., Anal. Biochem., 164: 44, 1987; Gibson, et al., EMBO J., 6(8): 2457, 1987; Dower, et al., Genetic Engineering, 12: 275, 1990; Mozo, et al., Plant Molecular Biology, 16: 917, 1991), thereby affording an efficient method of gene therapy, for example.
- an electrode apparatus for the application of electroporation to a portion of the body of a patient, comprises a support member, a plurality of needle electrodes adjustably mounted on said support member for insertion into tissue at selected positions and distances from one another, and means including a signal generator responsive to said distance signal for applying an electric signal to the electrodes proportionate to the distance between said electrodes for generating an electric field of a predetermined strength.
- Another aspect of the invention includes needles that function for injection of therapeutic substances into tissue and function as electrodes for generating electric fields for portion of cells of the tissue.
- FIG. 1 is a side elevation view, in section of a needle assembly in accordance with a preferred embodiment of the invention.
- FIG. 2 is a bottom view of the embodiment of FIG. 1 .
- FIG. 3 is an assembly drawing showing a perspective view of an alternate embodiment of the invention.
- FIG. 4 is a perspective view of the embodiment of FIG. 3 shown assembled.
- FIG. 5 is a perspective view of a selector switch for the electrode assembly of FIG. 4 .
- FIGS. 6 a - 6 b is a diagrammatic illustration of selected contact positions of the switch of FIG. 5 .
- FIG. 7 is a perspective view of a further embodiment of the invention.
- FIG. 8 is a perspective view of a still further embodiment of the invention.
- FIGS. 9 a - 9 d is a top plan view, illustrating a preferred form of electrodes and sequence of use.
- FIG. 11 is an illustration of tumor growth of Panc-3 cells after ECT with bleomycin in nude mice.
- FIGS. 12 a and 12 b show the tumor volume after 20 and 34 days of ECT with bleomycin, respectively, in non-small cell lung carcinoma (NSCLC) xenografted nude mice.
- NSCLC non-small cell lung carcinoma
- FIG. 13 shows the tumor volume after 34 days of ECT with bleomycin in non-small cell lung carcinoma (NSCLC) xenografted nude mice.
- the arrow indicates retreatment of one mouse at day 27.
- FIGS. 14 a and 14 b show pre-pulse dosing with neocarcinostatin in Panc-3 and NSCLC, respectively, in the nude mouse model.
- FIGS. 14 c and 14 d show post-pulse dosing with neocarcinostatin in Panc-3 in the nude mouse model.
- molecules includes pharmacological agents, genes, antibodies or other proteins.
- electroporation consists of infusion of an anticancer drug and electroporation of the drug into the tumor by applying voltage pulses between electrodes disposed on opposite sides of the tumor, called electrochemotherapy (ECT).
- ECT electrochemotherapy
- the present invention was devised primarily for enabling ECT such as that reported by Okino and Mir et al to be carried out on non-surface tumors such as those inside the body. However, it may be utilized for other therapeutic applications.
- the needle assembly comprises an elongated tubular support body 12 which is preferably in the form of a hollow stainless steel shaft.
- a center needle mount 14 is mounted on the lower end of the shaft 12 and has a central bore 16 for receiving and guiding a center needle 18 .
- the shaft 12 includes a needle exit slot 20 through which the needle electrode 18 extends from the interior thereof to the exterior where it is secured by a clamp 22 to the outside of the tube 12 .
- the upper end of the electrode 18 may be secured to a screw 24 for connection to an electrical circuit.
- the lower end of the tubular holder 12 includes threats 26 for threatably receiving a collar 28 for mounting a plurality of needles and a stop collar 30 for stopping or locking the collar 28 in position.
- a plurality of needles 32 are mounted in grooves 34 equally spaced around the outer surface of the needle collar 28 . This provides a circular array of equally spaced needles, eight in number in the illustrated embodiment.
- the needles are held in place by a band clamp 36 , having the ends clamped together by a screw or nut and bolt 38 which also serves as an electrical connection for the needles.
- the band clamp 36 directly engages and holds the needles in place.
- This electrode assembly is designed to apply electrical energy to living tissue when the needles are inserted into the tissue.
- the center needle 18 acts as one electrode, such as an anode or cathode, and the other or annular arrangement of needles 32 functions as the opposite electrode. All of these needles are held in fixed positions when the clamps are installed and secured.
- One or more of the needles may be cannular or tubular in form for injecting molecules of genes, pharmaceutical or other substances into the tissue.
- the center needle should be adjusted in order to achieve the desired tissue penetration. This is done by releasing the pressure of the center needle clamp 22 and sliding the center needle 18 outwardly or inwardly, as seen in FIG. 1 , so that it extends from the center needle guide 14 to desired penetration distance. The needle is then clamped in position. Thereafter annular needles 32 are adjusted to achieve the desired penetration into the tissue. This can be accomplished by releasing the pressure of the band clamp 36 and sliding the needles 32 into the desired position. Minor adjustments can also be made by moving the needle collar 28 toward and away from the end of the shaft 12 . A therapeutic substance may be injected into the tissue through one or more of these needles or by a separate means.
- the shaft 12 is grasped and the needles are inserted into the tissue to the desired depth. Thereafter, a suitable pulse generator is connected to the electrode assembly and the appropriate voltage applied to the electrodes. A suitable quantity of therapeutic substance such as genes or molecules of a suitable chemical or pharmaceutical for treatment of the tissue is injected into the tissue before the voltage is applied.
- a modification to this electrode assembly could include a solid non-penetrating electrode (not shown) in place of the center needle.
- the non-penetrating center electrode could be any suitable shape conductor such as a button or plate attached to the end of the shaft 12 to contact the surface tissue.
- the annular needle arrangement would be adjusted to penetrate the tissue at the desired depth when the center electrode is resting on a tissue surface. Electrical energy would flow from the penetrating needles through the tissue and to the central electrode on the surface. These arrangements can be utilized to treat near surface rumors where the circular array of electrodes are designed to encircle the tumor.
- the central electrode is positioned such that the electrical energy flows through the tumor to the central electrode.
- the needle 28 collar can also be adjusted to position it from the end of the shaft 12 so that insertion of the center and annular needles can be directly observed.
- the needle collar 28 can have any size or configuration to encircle the tissue area to be treated.
- FIGS. 3 and 4 an alternate embodiment of a circular array needle electrode assembly is illustrated and designated generally by the numeral 40 .
- This needle assembly comprises a circular array of needles 42 through 52 , which are mounted in equally spaced relation in a hub 54 mounted on an elongated cylindrical shaft 56 .
- the hub 54 is preferably of a suitably selected diameter to provide the desired diameter of the arrays to position around a tumor or other tissue to be treated.
- One or more of the needles may be hollow to enable the injection of molecules of a therapeutic substance, as will be more fully described hereinafter.
- An electrical connector socket assembly comprises a body member 58 having a central opening or bore 60 for receipt of shaft 56 and, an annular array of a plurality of sockets 62 through 72 for receipt of the ends of needles 42 through 52 .
- the sockets 62 through 72 electrically connect the needles to leads 74 through 84 which connect to a distributing switch, as will be subsequently described.
- the electrical connector socket 58 fits onto shaft 56 with the end of the needles extending into the electrical sockets 62 through 72 for connecting to the leads 74 through 84 .
- the shaft 56 which mounts the needle array hub 54 and the socket assembly 58 mounts onto a holder 86 adapted to be held in the hand.
- the holder 86 has an elongated cylindrical configuration adapted to be held in the hand for manipulation.
- the holder 86 has a forward socket and including a forwardly extending tubular shaft 88 having a bore 90 into which shaft 56 extends while the shaft 88 extends into a bore (not shown) within the connector member 58 .
- the shaft 56 extends into bore 90 and has a annular groove or recess 92 which is engaged by a retainer latch which comprises a transverse plug 94 in a bore 96 biased to one side and including a bore 98 in which the annular slot 92 extends and is retained in the holder.
- a spring 102 mounted in bore 96 biases plug 94 to the latched position.
- the shaft 56 may be released for removal by pressing on end 100 of plug 94 .
- the holder when assembled as shown in FIG. 4 may be grasped in the hand and the needles inserted into a selected tissue area.
- the needles 42 - 52 are preferably spaced and positioned to surround the selected tissue of treatment.
- One or more of the needles 42 - 52 may be hollow to enable the injection of the desired therapeutic substance.
- the electrode leads 74 - 84 are then connected in a preferred arrangement to a rotatable switch assembly, as shown in FIG. 5 , which enables the selection of opposed pairs of the needles for activation or the application of the electrical potential.
- the switch assembly designated generally by the numeral 104 comprises a stationary housing 106 which, in the illustrated embodiment, is generally cylindrical in configuration and in which is mounted a rotor 108 with spaced contacts 110 and 112 connected by a pair of conductors 114 and 116 to a pulse power generator 115 .
- the rotor contacts 110 and 112 are positioned within housing 106 to engage annular contacts 118 , 120 , 122 , 124 , 126 and 128 to which leads 74 - 84 are connected.
- the rotor 108 has an internal portion having contacts 110 and 112 each of which bridge between two contacts 118 - 128 to which the leads 74 through 84 are connected to connect the source of power.
- the internal contacts 110 and 112 rotate with the rotor 108 and can be selectively positioned in conductive relation with pairs of the internal contacts 118 - 128 to thereby activate opposed pairs of the needle electrodes. This enables the operator to selectively position the electrodes surrounding a selected tissue and to selectively apply the direction of the electrical field as desired for optimum treatment.
- the rotor 108 enables the field to be selectively generated around or across the tissue from all directions.
- the electrode assembly designated generally by the numeral 130 includes a pair of spaced apart arrays 132 and 134 of conductive needle electrodes 136 and 138 mounted on a dielectric carrier or support member 140 .
- the needle array 132 is held in a fixed clamp 142 which allows the needles 136 to be adjusted in depth relative to the support 140 .
- the needles 138 are mounted in a moveable clamp 146 which is adjustably mounted on support member 140 by a clamp screw 148 .
- the needles 136 and 138 are each provided with a penetration stop 144 .
- the gap spacing clamp screw 148 secures the clamp 146 in selected positions on the support 140 .
- a gap spacing sensor 150 senses the distance between the needle arrays 132 and 134 and generates a signal that is sent to the pulse generator via conductor cable 152 .
- a pulse generator is connected to the needle electrodes by means of cables 154 and 156 .
- This embodiment comprises a base holder member 158 having a plurality of adjacently positioned parallel slots 160 into which selected needles 162 and 164 may be positioned in selected spaced relation.
- This holder may serve to mount a pair of oppositely polarized needle electrodes 162 and 164 , as illustrated. These can be selectively positioned in selected space relationship to be disposed on opposite sides of a selected tissue.
- the needles are clamped into the slots by a clamp or plate 159 .
- the holder may be used in combination with an additional holder for provision of multiple arrays on opposite sides of a selected tissue.
- the illustrated needles may be connected by conductors 166 and 168 to a suitable pulse generator.
- the combination electrodes may take the form of separate needles 170 and 172 which may be first inserted into or beside a selected tissue area such as on opposite sides of a tumor 194 as illustrated. Thereafter the needles may be connected to a syringe or other source of molecules and used to inject a selected molecular solution into the tissue area.
- the needles may be non-conductive and a pair of electrodes 176 and 178 , as illustrated in FIG. 9 b , are selectively fed through the bore or lumen of the respective needles into the tissue, as illustrated, and thereafter the needle is removed, as shown in FIG. 9 c .
- the electrodes 176 and 178 are each provided with an elongated insulated conductor 180 and 182 with conductive tips 184 and 186 .
- a pair of conductors 188 and 190 from a suitable power generator may then be connected to the ends of the conductors of the electrodes by micro clamps 192 and 194 , as shown in 9 d , and an electric potential applied across the electrodes.
- This generates a field in the tissue and electroporates the cells of the selected tissue, such as a tumor or the like. This electroporation enables the selected molecules to enter the cells of the tissue and more efficiently kill or alter the cells as desired.
- This form of needle and electrode may be used with any or all the above described assemblies.
- needle electrode assemblies as above described, enable the in vivo positioning of electrodes in or adjacent to subsurface tumors or other tissue. While the focus of the present application has been on electrochemotherapy, the embodiment of the subject invention may be applied to other treatments, such as gene therapy of certain organs of the body.
- the nature of the electric field to be generated is determined by the nature of the tissue, the size of the selected tissue and its location. It is desirable that the field be as homogenous as possible and of the correct amplitude. Excessive field strength results in lysing of cells, whereas a low field strength results in reduced efficacy.
- the electrodes may be mounted and manipulated in many ways including but not limited to those in the parent application. The electrodes may be conveniently manipulated on and by forceps to internal position.
- the waveform of the electrical signal provided by the pulse generator can be an exponentially decaying pulse, a square pulse, a unipolar oscillating pulse train or a bipolar oscillating pulse train.
- the electric field strength can be 0.2 kV/cm to 20 kV/cm.
- the pulse length can be ten ⁇ s to 100 ms. There can be one to one hundred pulses.
- the waveform, electric field strength and pulse duration are also dependent upon the type of cells and the type of molecules that are to enter the cells via electroporation.
- the various parameters including electric field strengths required for the electroporation of any known cell is generally available from the many research papers reporting on the subject, as well as from a database maintained by Genetronics, Inc., San Diego, Calif., assignee of the subject application.
- the electric fields needed for in vivo cell electroporation, such as ECT, are similar in amplitude to the fields required for cells in vitro. These are in the range of from 100 V/cm to several kV/cm. This has been verified by the inventors own experiments and those of others reported in scientific publications.
- the first in vivo application of pulsed electric fields in the chemotherapy field to treat tumors was reported in 1987 by Okino in Japan.
- Pulse generators for carrying out the procedures described herein are and have been available on the market for a number of years.
- One suitable signal generator is the ELECTRO CELL MANIPULATOR Model ECM 600 commercially available from GENETRONICS, INC. of San Diego, Calif., U.S.A.
- the ECM 600 signal generator generates a pulse from the complete discharge of a capacitor which results in an exponentially decaying waveform.
- the electric signal generated by this signal generator is characterized by a fast rise time and an exponential tail.
- the electroporation pulse length is set by selecting one of ten timing resistors marked R 1 through R 10 . They are active in both High Voltage Mode (HVM) (capacitance fixed at fifty microfarads) and Low Voltage Mode (LVM) (with a capacitance range from 25 to 3,175 microfarads).
- HVM High Voltage Mode
- LVM Low Voltage Mode
- the ECM 600 signal generator has a control knob that permits the adjustment of the amplitude of the set charging voltage applied to the internal capacitors from 50 to 500 volts in LVM and from 0.05 to 2.5 kV in the HVM.
- the amplitude of the electrical signal is shown on a display incorporated into the ECM 600 signal generator.
- This device further includes a plurality of push button switches for controlling pulse length, in the Low VM mode, by a simultaneous combination of resistors parallel to the output and a bank of seven selectable additive capacitors.
- the ECM 600 signal generator also includes a single automatic charge and pulse push button. This button may be depressed to initiate both charging of the internal capacitors to the set voltage and to deliver a pulse to the outside electrodes in an automatic cycle that takes less than five seconds.
- the manual button may be sequentially pressed to repeatedly apply the predetermined electric field.
- the therapeutic method of the invention utilizes a square wave pulse electroporation system.
- a square wave pulse electroporation system For example, the ElectroSquarePorator (T820), also available from GENETRONICS, INC., can be used.
- Square wave electroporation systems deliver controlled electric pulses that rise quickly to a set voltage, stay at that level for a set length of time (pulse length), and then quickly drop to zero. This type of system yields better transformation efficiency for the electroporation of plant protoplast and mammalian cell lines than an exponential decay system.
- the ElectroSquarePorator (T820) is the first commercially available square wave electropomtion system capable of generating up to 3000 volts.
- the pulse length can be adjusted from 5 ⁇ sec to 99 msec.
- the square wave electroporation pulses have a gentler effect on the cells which results in higher cell viability.
- the T820 ElectroSquarePorator is active in both the High Voltage Mode (HVM) (100-3000 volts) and the Low Voltage Mode (LVM) (50-500 volts).
- the pulse length for LVM is about 0.3 to 99 msec and for HVM, 5 to 99 ⁇ sec.
- the T820 has multiple pulsing capability from about 1 to 99 pulses.
- Saunders has compared the square wave with exponential decay pulses in the electroporation of plant protoplast. Square wave electroporation produced higher transformation efficiency than the exponential decay pulses. He also reported that the optimization of electroporation parameters is much easier with square wave pulses since sufficient transformation efficiency can be produced over a larger range of voltages (Saunders, Guide to Electroporation and Electrofusion , pp. 227-247, 1991).
- the therapeutic method of the invention includes electrotherapy, also referred to herein as electroporation-mediated therapy, using the apparatus of the invention for the delivery of macromolecules to a cell or tissue.
- macromolecule or “molecule” as used herein refers to drugs (e.g., chemotherapeutic agents), nucleic acids (e.g., polynucleotides), peptides and polypeptides, including antibodies.
- nucleic acids e.g., polynucleotides
- peptides e.g., polypeptides and polypeptides, including antibodies.
- polynucleotides include DNA, cDNA and RNA sequences.
- Drugs contemplated for use in the method of the invention are typically chemotherapeutic agents having an antitumor or cytotoxic effect.
- Such drugs or agents include bleomycin, neocarcinostatin, suramin, and cisplatin.
- Other chemotherapeutic agents will be known to those of skill in the art (see for example The Merck Index).
- the chemical composition of the agent will dictate the most appropriate time to administer the agent in relation to the administration of the electric pulse.
- a gene in a cell may be desirable to modulate the expression of a gene in a cell by the introduction of a molecule by the method of the invention.
- modulate envisions the suppression of expression of a gene when it is over-expressed, or augmentation of expression when it is underexpressed.
- nucleic acid sequences that interfere with the gene's expression at the translational level can be used. This approach utilizes, for example, antisense nucleic acid, ribozymes, or triplex agents to block transcription or translation of a specific mRNA, either by masking that mRNA with an antisense nucleic acid or triplex agent, or by cleaving it with a ribozyme.
- Antisense nucleic acids are DNA or RNA molecules that are complementary to at least a portion of a specific mRNA molecule (Weintraub, Scientific American, 262: 40, 1990). In the cell, the antisense nucleic acids hybridize to the corresponding mRNA, forming a double-stranded molecule. The antisense nucleic acids interfere with the translation of the mRNA, since the cell will not translate a mRNA that is double-stranded. Antisense oligomers of about 15 nucleotides are preferred, since they are easily synthesized and are less likely to cause problems than larger molecules when introduced into the target cell. The use of antisense methods to inhiiit the in vitro translation of genes is well known in the art (Marcus-Sakura, Anal. Biochem ., 172: 289, 1988).
- triplex strategy Use of an oligonucleotide to stall transcription is known as the triplex strategy since the oligomer winds around double-helical DNA, forming a three-strand helix. Therefore, these triplex compounds can be designed to recognize a unique site on a chosen gene (Maher, et al., Antisense Res. and Dev., 1(3): 227, 1991; Helene, C., Anticancer Drug Design, 6(6): 569, 1991).
- Ribozymes are RNA molecules possessing the ability to specifically cleave other singles-tranded RNA in a manner analogous to DNA restriction endonucleases. Through the modification of nucleotide sequences which encode these RNAs, it is possible to engineer molecules that recognize specific nucleotide sequences in an RNA molecule and cleave it (Cech, J. Amer. Med. Assn., 260: 3030, 1988). A major advantage of this approach is that, because they are sequence-specific, only mRNAs with particular sequences are inactivated.
- ribozymes There are two basic types of ribozymes namely, tetrahymena-type (Hasselhoff, Nature, 334: 585, 1988) and “hammerhead”-type. Tetrahymena-type ribozymes recognize sequences which are four bases in length, while “hammerhead”-type ribozymes recognize base sequences 11-18 bases in length. The longer the recognition sequence, the greater the likelihood that the sequence will occur exclusively in the target mRNA species. Consequently, hammerhead-type ribozymes are preferable to tetrahymena-type ribozymes for inactivating a specific mRNA species and 18-based recognition sequences are preferable to shorter recognition sequences.
- the present invention also provides gene therapy for the treatment of cell proliferative or immunologic disorders mediated by a particular gene or absence thereof. Such therapy would achieve its therapeutic effect by introduction of a specific sense or antisense polynucleotide into cells having the disorder. Delivery of polynucleotides can be achieved using a recombinant expression vector such as a chimeric virus, or the polynucleotide can be delivered as “naked” DNA for example.
- RNA virus such as a retrovirus
- retroviral vector is a derivative of a murine or avian retrovirus.
- retroviral vectors in which a single foreign gene can be inserted include, but are not limited to: Moloney murine leukemia virus (MoMuLV), Harvey murine sarcoma virus (HaMuSV), murine mammary tumor virus (MuMTV), and Rous Sarcoma Virus (RSV).
- a vector such as the gibbon ape leukemia virus (GALV) can be utilized.
- a number of additional retroviral vectors can incorporate multiple genes. All of these vectors can transfer or incorporate a gene for a selectable marker so that transduced cells can be identified and generated.
- Therapeutic peptides or polypeptides may also be included in the therapeutic method of the invention.
- immunomodulatory agents and other biological response modifiers can be administered for incorporation by a cell.
- biological response modifiers is meant to encompass substances which are involved in modifying the immune response.
- immune response modifiers include such compounds as lymphokines. Lymphokines include tumor necrosis factor, interleukins 1,2, and 3, lymphotoxin, macrophage activating factor, migration inhibition factor, colony stimulating factor, and alpha-interferon, beta-interferon, and gamma-interferon and their subtypes.
- polynucleotides which encode metabolic enzymes and proteins, including antiangiogenesis compounds, e.g., Factor VIII or Factor IX.
- the macromolecule of the invention also includes antibody molecules.
- antibody as used herein is meant to include intact molecules as well as fragments thereof, such as Fab and F(ab′) 2 .
- Administration of a drug, polynucleotide or polypeptide, in the method of the invention can be, for example, parenterally by injection, rapid infusion, nasopharyngeal absorption, dermal absorption, and orally.
- a chemotherapeutic or other agent can be administered locally, systemically or directly injected into the tumor.
- a drug for example, is administered directly into the tumor, it is advantageous to inject the drug in a “fanning” manner.
- nning refers to administering the drug by changing the direction of the needle as the drug is being injected or by multiple injections in multiple directions like opening up of a hand fan, rather than as a bolus, in order to provide a greater distribution of drug throughout the tumor.
- the drug e.g., injected
- the results are greatly improved by increasing the volume to 150 ⁇ l.
- the injection should be done very slowly and at the periphery rather than at the center of the tumor where the intertitial pressure is very high.
- the molecule is administered substantially contemporaneously with the electroporation treatment.
- substantially contemporaneously means that the molecule and the electroporation treatment are administered reasonably close together with respect to time.
- the administration of the molecule or therapeutic agent can at any interval, depending upon such factors, for example, as the nature of the tumor, the condition of the patient, the size and chemical characteristics of the molecule and half-life of the molecule.
- Preparations for parenteral administration include sterile or aqueous or non-aqueous solutions, suspensions, and emulsions.
- non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate.
- Carriers for occlusive dressings can be used to increase skin permeability and enhance antigen absorption.
- Liquid dosage forms for oral administration may generally comprise a liposome solution containing the liquid dosage form. Suitable forms for suspending the liposomes include emulsions, suspensions, solutions, syrups, and elixirs containing inert diluents commonly used in the art, such as purified water.
- compositions can also include adjuvants, wetting agents, emulsifying and suspending agents. Further, vasoconstrictor agents can be used to keep the therapeutic agent localized prior to pulsing.
- Any cell can be treated by the method of the invention.
- the illustrative examples provided herein demonstrate the use of the method of the invention for the treatment of tumor cells, e.g., pancreas and lung.
- Other cell proliferative disorders are amenable to treatment by the electroporation method of the invention.
- the term “cell proliferative disorder” denotes malignant as well as non-malignant cell populations which often appear to differ from the surrounding tissue both morphologically and genotypically. Malignant cells (i.e., tumors or cancer) develop as a result of a multi-step process.
- the method of the invention is useful in treating malignancies or other disorders of the various organ systems, particularly, for example, cells in the pancreas and lung, and also including cells of heart, kidney, muscle, breast, colon, prostate, thymus, testis, and ovary.
- the subject is human.
- ECT electrochemotherapy
- Panc-3 poorly differentiated human pancreatic tumor
- the single treatment procedure involved injection of bleomycin (0.5 units in 0.15 ml saline) intratumorally, using farming, as described herein followed by application of six square wave electrical pulses, ten minutes later, using proprietary needle array electrodes arranged along the circumference of a circle 1 cm in diameter. Needle array of variable diameters (e.g., 0.5 cm, 0.75 cm and 1.5 cm can also be used to accommodate tumors of various sizes. Stoppers of various heights can be inserted at the center of the array to make the penetration depth of the needles into the tumor variable. A built-in mechanism allowed switching of electrodes for maximum coverage of the tumor by the pulsed field.
- the electrical parameters were: 1300 V/cm and 6 ⁇ 99 ⁇ s pulses spaced at 1 sec interval.
- the tumor cell line Pant-3 a poorly differentiated adenocarcinoma cell line of the pancreas, was supplied by Anticancer, Inc., San Diego.
- the tumor dimensions were measured and the tumor volume calculated using the formula: (II/6) ⁇ a ⁇ b ⁇ c where a, b, and c are, respectively, the length, width and thickness of the tumor.
- each mouse in the D+E+group was pulsed from a BTX T820 square wave electroporator with a set of needle array electrodes as described in the present invention. Electrical parameters used were as follows: field strength 1300 V/cm, 6 pulses of 99 ⁇ s each, at 1 sec interval.
- mice were monitored every day for mortality and any signs of a diseased state were noted.
- the tumor dimensions were measured at regular intervals and tumor growth regression/progression monitored.
- Another set of nude mice with xenografts of non-small cell lung cancer line was also treated by the same procedure as for the Panc-3 tumors.
- FIGS. 10 a and 10 b show the analysis of the tumor volume determined over a 43 day period after ECT using bleomycin for the Panc-3 tumors. There was a dramatic difference between the untreated and treated mice in terms of tumor volume. There was essentially no detectable tumor after approximately 24 days of treatment.
- the results of FIG. 10 are also summarized in Table 1 below. An illustration of the actual regression of the tumor is shown in FIG. 11 .
- the Panc-3 experiment was repeated using a non-small cell lung cancer cell line (NSCLC), 177 (Anticancer, San Diego, Calif.). The results were similar to that found with bleomycin and Panc-3 as shown in FIGS. 12 a and 12 b .
- NSCLC non-small cell lung cancer cell line
- 177 Anticancer, San Diego, Calif.
- the results were similar to that found with bleomycin and Panc-3 as shown in FIGS. 12 a and 12 b .
- a tumor that had recurred was retreated at day 27 ( FIG. 13 ) and after 7 days, there was no evidence of tumor.
- the Panc-3 and NSCLC models were utilized with the drug neocarcinostatin (NCS) following the same procedures as outlined above.
- NCS drug neocarcinostatin
- FIGS. 14 a and 14 b pre-pulse dosing with NCS in a manner similar to that used for the bleomycin studies, was not effective in reducing tumor size at all. It was believed that due to the low isoelectric point of NCS, electrostatic interaction prevented the drug from entering the tumor cell. Therefore, the experiment was repeated by pulsing first and injecting NCS post-pulse.
- FIG. 14 c shows the initial tumor volume (I) as compared to the final tumor volume (F) at day 13 for 7 mice treated (Mouse ID 1-7). In several of the mice (ID 1, 2, 4, and 7), an increase in tumor volume was observed, but appeared to be due to edema. However, as shown in FIG. 14 d , when a separate group of 5 mice were examined at day 23 , all mice showed a marked reduction in tumor volume.
- FIGS. 14 a and b A comparison of FIGS. 14 a and b with 14 c and d indicated that post-pulse with NCS was more effective than pre-pulse administration for NCS.
- Pancreatic cancer Pancreatic cancer
- NSCLC Non-small cell lung cancer
Abstract
A method for in vivo electrotherapy, or electroporation-mediated therapy, using a needle array apparatus is provided. Treatment of tumors with a combination of electroporation using the apparatus of the invention, and a chemotherapeutic agent, caused regression of tumors in vivo.
Description
- The present application is a Continuation-in-Part of co-pending application Ser. No. 08/467,566, filed on Jun. 6, 1995, which is a Continuation-in-Part of co-pending application Ser. No. 08/042,039 filed on Apr. 1, 1993.
- The present invention relates to the treatment of ailments in humans and other mammals, and more particularly, to an improved method and apparatus for the application of controlled electric fields for in vivo delivery of genes and pharmaceutical compounds into live cells of a patient by electroporation.
- In the 1970's it was discovered that electric fields could be used to create pores in cells without causing permanent damage to them. This discovery made possible the insertion of large molecules into cell cytoplasm. It is known that genes and other molecules such as pharmacological compounds can be incorporated into live cells through a process known as electroporation. The genes or other molecules are mixed with the live cells in a buffer medium and short pulses of high electric fields are applied. The cell membranes are transiently made porous and the genes or molecules enter the cells. There they can modify the genome of the cell.
- Electroporation has been recently suggested as one approach to the treatment of certain diseases such as cancer. For example, in the treatment of certain types of cancer with chemotherapy it is necessary to use a high enough dose of a drug to kill the cancer cells without killing an unacceptable high number of normal cells. If the chemotherapy drug could be inserted directly inside the cancer cells, this objective could be achieved. Some of the best anti-cancer drugs, for trample, bleomycin, normally cannot penetrate the membranes of certain cancer cells. However, electroporation makes it possible to insert the bleomycin into the cells.
- One therapeutic application of electroporation is for cancer treatment. Experiments on laboratory mammals have been carried out and reported as follows: Okino, M., E. Kensuke, 1990. The Effects of a Single High Voltage Electrical Stimulation with an Anticancer Drug on in vivo Growing Malignant Tumors. Jap. Journal of Surgery. 20: 197-204. Mir, L. M., S. Orlowski, J. Belehradek Jr., and C. Paoletti. 1991. Electrochemotherapy Potentiation of Antitumor Effect of Bleomycin by Local Electric Pulses. Eur. J. Cancer. 27: 68-72. Clinical trials have been conducted and reported by Mir, L. M., M. Belehradek, C. Domenge, S. Orlowski, B. Poddevin, et al. 1991. Electrochemotherapy, a novel antitumor treatment: first clinical trial. C.R. Acad. Sci. Paris. 313: 613-618.
- This treatment is carried out by infusing an anticancer drug directly into the tumor and applying an electric field to the tumor between a pair of electrodes. The field strength must be adjusted reasonably accurately so that electroporation of the cells of the tumor occurs without damage, or at least minimal damage, to any normal or healthy cells. This can normally be easily carried out with external tumors by applying the electrodes to opposite sides of the tumor so that the electric field is between the electrodes. The distance between the electrodes can then be measured and a suitable voltage according to the formula E=V/d can then be applied to the electrodes (E=electric field strength in V/cm; V=voltage in volts; and d=distance in cm). When internal tumors are to be treated, it is not easy to properly locate electrodes and measure the distance between them. In the aforementioned parent application, there is disclosed a system of electrodes for in vivo electroporation wherein the electrodes may be inserted into body cavities. In a related U.S. Pat. No. 5,273,25 a syringe for injecting molecules and macromolecules for electroporation utilizes needles for injection which also function as electrodes. This construction enables the subsurface placement of electrodes. It would be desirable to have an electrode apparatus having electrodes that can be inserted into or adjacent tumors so that predetermined electric fields can be generated in the tissue for electroporation of the cells of the tumor.
- Studies have also shown that large size nucleotide sequences (up to 630 kb) can be introduced into mammalian cells via electroporation (Eanault, et al., Gene (Amsterdam), 144(2): 205, 1994; Nucleic Acids Research, 15(3): 1311, 1987; Knutson, et al., Anal. Biochem., 164: 44, 1987; Gibson, et al., EMBO J., 6(8): 2457, 1987; Dower, et al., Genetic Engineering, 12: 275, 1990; Mozo, et al., Plant Molecular Biology, 16: 917, 1991), thereby affording an efficient method of gene therapy, for example.
- Accordingly, it is a primary object of the present invention to provide an improved apparatus that can be conveniently and effectively positioned to generate predetermined electric fields in pre-selected tissue.
- It is another principal object of the present invention to provide an improved apparatus that provides an effective and convenient means for positioning electrodes into tissue for the injection of therapeutic compounds into the tissue and application of electric fields to the tissue.
- In accordance with a primary aspect of the present invention an electrode apparatus for the application of electroporation to a portion of the body of a patient, comprises a support member, a plurality of needle electrodes adjustably mounted on said support member for insertion into tissue at selected positions and distances from one another, and means including a signal generator responsive to said distance signal for applying an electric signal to the electrodes proportionate to the distance between said electrodes for generating an electric field of a predetermined strength.
- Another aspect of the invention includes needles that function for injection of therapeutic substances into tissue and function as electrodes for generating electric fields for portion of cells of the tissue.
- In yet another aspect of the invention is provided a therapeutic method utilizing the needle array apparatus for the treatment of cells, particularly tumor cells.
-
FIG. 1 is a side elevation view, in section of a needle assembly in accordance with a preferred embodiment of the invention. -
FIG. 2 is a bottom view of the embodiment ofFIG. 1 . -
FIG. 3 is an assembly drawing showing a perspective view of an alternate embodiment of the invention. -
FIG. 4 is a perspective view of the embodiment ofFIG. 3 shown assembled. -
FIG. 5 is a perspective view of a selector switch for the electrode assembly ofFIG. 4 . -
FIGS. 6 a-6 b is a diagrammatic illustration of selected contact positions of the switch ofFIG. 5 . -
FIG. 7 is a perspective view of a further embodiment of the invention. -
FIG. 8 is a perspective view of a still further embodiment of the invention. -
FIGS. 9 a-9 d is a top plan view, illustrating a preferred form of electrodes and sequence of use. -
FIGS. 10 a and 10 b show the tumor volume after 43 days of ECT with bleomycin in Panc-3 xenografted nude mice. (D=drug; E=electroporation) -
FIG. 11 is an illustration of tumor growth of Panc-3 cells after ECT with bleomycin in nude mice. -
FIGS. 12 a and 12 b show the tumor volume after 20 and 34 days of ECT with bleomycin, respectively, in non-small cell lung carcinoma (NSCLC) xenografted nude mice. (D=drug; E=electroporation) -
FIG. 13 shows the tumor volume after 34 days of ECT with bleomycin in non-small cell lung carcinoma (NSCLC) xenografted nude mice. The arrow indicates retreatment of one mouse atday 27. (D=drug; E=electroporation) -
FIGS. 14 a and 14 b show pre-pulse dosing with neocarcinostatin in Panc-3 and NSCLC, respectively, in the nude mouse model. -
FIGS. 14 c and 14 d show post-pulse dosing with neocarcinostatin in Panc-3 in the nude mouse model. - As used herein the term “molecules” includes pharmacological agents, genes, antibodies or other proteins. One human therapeutic application of electroporation consists of infusion of an anticancer drug and electroporation of the drug into the tumor by applying voltage pulses between electrodes disposed on opposite sides of the tumor, called electrochemotherapy (ECT). The present invention was devised primarily for enabling ECT such as that reported by Okino and Mir et al to be carried out on non-surface tumors such as those inside the body. However, it may be utilized for other therapeutic applications.
- Referring to
FIG. 1 of the drawings, a needle assembly in accordance with preferred embodiment of the invention is illustrated and designated generally by the numeral 10. The needle assembly comprises an elongatedtubular support body 12 which is preferably in the form of a hollow stainless steel shaft. Acenter needle mount 14 is mounted on the lower end of theshaft 12 and has acentral bore 16 for receiving and guiding acenter needle 18. Theshaft 12 includes aneedle exit slot 20 through which theneedle electrode 18 extends from the interior thereof to the exterior where it is secured by aclamp 22 to the outside of thetube 12. - The upper end of the
electrode 18 may be secured to ascrew 24 for connection to an electrical circuit. The lower end of thetubular holder 12 includesthreats 26 for threatably receiving acollar 28 for mounting a plurality of needles and astop collar 30 for stopping or locking thecollar 28 in position. - A plurality of
needles 32 are mounted ingrooves 34 equally spaced around the outer surface of theneedle collar 28. This provides a circular array of equally spaced needles, eight in number in the illustrated embodiment. The needles are held in place by aband clamp 36, having the ends clamped together by a screw or nut and bolt 38 which also serves as an electrical connection for the needles. Theband clamp 36 directly engages and holds the needles in place. - This electrode assembly is designed to apply electrical energy to living tissue when the needles are inserted into the tissue. The
center needle 18 acts as one electrode, such as an anode or cathode, and the other or annular arrangement ofneedles 32 functions as the opposite electrode. All of these needles are held in fixed positions when the clamps are installed and secured. One or more of the needles may be cannular or tubular in form for injecting molecules of genes, pharmaceutical or other substances into the tissue. - In operation the center needle should be adjusted in order to achieve the desired tissue penetration. This is done by releasing the pressure of the
center needle clamp 22 and sliding thecenter needle 18 outwardly or inwardly, as seen inFIG. 1 , so that it extends from thecenter needle guide 14 to desired penetration distance. The needle is then clamped in position. Thereafterannular needles 32 are adjusted to achieve the desired penetration into the tissue. This can be accomplished by releasing the pressure of theband clamp 36 and sliding theneedles 32 into the desired position. Minor adjustments can also be made by moving theneedle collar 28 toward and away from the end of theshaft 12. A therapeutic substance may be injected into the tissue through one or more of these needles or by a separate means. - After all needles are adjusted to the proper penetration, the
shaft 12 is grasped and the needles are inserted into the tissue to the desired depth. Thereafter, a suitable pulse generator is connected to the electrode assembly and the appropriate voltage applied to the electrodes. A suitable quantity of therapeutic substance such as genes or molecules of a suitable chemical or pharmaceutical for treatment of the tissue is injected into the tissue before the voltage is applied. - A modification to this electrode assembly could include a solid non-penetrating electrode (not shown) in place of the center needle. The non-penetrating center electrode could be any suitable shape conductor such as a button or plate attached to the end of the
shaft 12 to contact the surface tissue. The annular needle arrangement would be adjusted to penetrate the tissue at the desired depth when the center electrode is resting on a tissue surface. Electrical energy would flow from the penetrating needles through the tissue and to the central electrode on the surface. These arrangements can be utilized to treat near surface rumors where the circular array of electrodes are designed to encircle the tumor. The central electrode is positioned such that the electrical energy flows through the tumor to the central electrode. - Other advantages of this electrode assembly are that all needles 18 and 32 can be independently adjusted to achieve the desired penetration. The
needle 28 collar can also be adjusted to position it from the end of theshaft 12 so that insertion of the center and annular needles can be directly observed. In addition, theneedle collar 28 can have any size or configuration to encircle the tissue area to be treated. - Referring to
FIGS. 3 and 4 an alternate embodiment of a circular array needle electrode assembly is illustrated and designated generally by the numeral 40. This needle assembly comprises a circular array ofneedles 42 through 52, which are mounted in equally spaced relation in ahub 54 mounted on an elongatedcylindrical shaft 56. Thehub 54 is preferably of a suitably selected diameter to provide the desired diameter of the arrays to position around a tumor or other tissue to be treated. One or more of the needles may be hollow to enable the injection of molecules of a therapeutic substance, as will be more fully described hereinafter. - An electrical connector socket assembly comprises a
body member 58 having a central opening or bore 60 for receipt ofshaft 56 and, an annular array of a plurality ofsockets 62 through 72 for receipt of the ends ofneedles 42 through 52. Thesockets 62 through 72 electrically connect the needles to leads 74 through 84 which connect to a distributing switch, as will be subsequently described. - The
electrical connector socket 58 fits ontoshaft 56 with the end of the needles extending into theelectrical sockets 62 through 72 for connecting to theleads 74 through 84. Theshaft 56 which mounts theneedle array hub 54 and thesocket assembly 58 mounts onto aholder 86 adapted to be held in the hand. Theholder 86 has an elongated cylindrical configuration adapted to be held in the hand for manipulation. Theholder 86 has a forward socket and including a forwardly extendingtubular shaft 88 having abore 90 into whichshaft 56 extends while theshaft 88 extends into a bore (not shown) within theconnector member 58. Theshaft 56 extends intobore 90 and has a annular groove orrecess 92 which is engaged by a retainer latch which comprises atransverse plug 94 in abore 96 biased to one side and including abore 98 in which theannular slot 92 extends and is retained in the holder. Aspring 102 mounted inbore 96 biases plug 94 to the latched position. Theshaft 56 may be released for removal by pressing onend 100 ofplug 94. - The holder when assembled as shown in
FIG. 4 may be grasped in the hand and the needles inserted into a selected tissue area. The needles 42-52 are preferably spaced and positioned to surround the selected tissue of treatment. One or more of the needles 42-52, as previously explained, may be hollow to enable the injection of the desired therapeutic substance. The electrode leads 74-84 are then connected in a preferred arrangement to a rotatable switch assembly, as shown inFIG. 5 , which enables the selection of opposed pairs of the needles for activation or the application of the electrical potential. - The switch assembly designated generally by the numeral 104 comprises a
stationary housing 106 which, in the illustrated embodiment, is generally cylindrical in configuration and in which is mounted arotor 108 with spacedcontacts conductors pulse power generator 115. Therotor contacts housing 106 to engageannular contacts - Referring to
FIGS. 6 a, b and c, therotor 108 has an internalportion having contacts internal contacts rotor 108 and can be selectively positioned in conductive relation with pairs of the internal contacts 118-128 to thereby activate opposed pairs of the needle electrodes. This enables the operator to selectively position the electrodes surrounding a selected tissue and to selectively apply the direction of the electrical field as desired for optimum treatment. Therotor 108 enables the field to be selectively generated around or across the tissue from all directions. - Referring to
FIG. 7 an alternate embodiment of an electric field generating array of parallel adjustably positionable electrodes, as disclosed in the parent application, is illustrated. The electrode assembly designated generally by the numeral 130 includes a pair of spaced apartarrays conductive needle electrodes support member 140. Theneedle array 132 is held in a fixedclamp 142 which allows theneedles 136 to be adjusted in depth relative to thesupport 140. - The
needles 138 are mounted in amoveable clamp 146 which is adjustably mounted onsupport member 140 by aclamp screw 148. Theneedles penetration stop 144. The gapspacing clamp screw 148 secures theclamp 146 in selected positions on thesupport 140. Agap spacing sensor 150 senses the distance between theneedle arrays conductor cable 152. A pulse generator is connected to the needle electrodes by means ofcables - Referring to
FIG. 8 , details of a needle holder or template for various arrangements for establishing a spaced pair or parallel arrays of needles is illustrated. This embodiment comprises abase holder member 158 having a plurality of adjacently positionedparallel slots 160 into which selectedneedles needle electrodes plate 159. In addition, the holder may be used in combination with an additional holder for provision of multiple arrays on opposite sides of a selected tissue. The illustrated needles may be connected byconductors - Referring to
FIGS. 9 a through 9 d, an additional aspect of the invention is illustrated. As more clearly illustrated, the combination electrodes may take the form ofseparate needles tumor 194 as illustrated. Thereafter the needles may be connected to a syringe or other source of molecules and used to inject a selected molecular solution into the tissue area. The needles may be non-conductive and a pair ofelectrodes FIG. 9 b, are selectively fed through the bore or lumen of the respective needles into the tissue, as illustrated, and thereafter the needle is removed, as shown inFIG. 9 c. Theelectrodes insulated conductor conductive tips - A pair of
conductors micro clamps 192 and 194, as shown in 9 d, and an electric potential applied across the electrodes. This generates a field in the tissue and electroporates the cells of the selected tissue, such as a tumor or the like. This electroporation enables the selected molecules to enter the cells of the tissue and more efficiently kill or alter the cells as desired. This form of needle and electrode may be used with any or all the above described assemblies. - These needle electrode assemblies, as above described, enable the in vivo positioning of electrodes in or adjacent to subsurface tumors or other tissue. While the focus of the present application has been on electrochemotherapy, the embodiment of the subject invention may be applied to other treatments, such as gene therapy of certain organs of the body.
- The nature of the electric field to be generated is determined by the nature of the tissue, the size of the selected tissue and its location. It is desirable that the field be as homogenous as possible and of the correct amplitude. Excessive field strength results in lysing of cells, whereas a low field strength results in reduced efficacy. The electrodes may be mounted and manipulated in many ways including but not limited to those in the parent application. The electrodes may be conveniently manipulated on and by forceps to internal position.
- The waveform of the electrical signal provided by the pulse generator can be an exponentially decaying pulse, a square pulse, a unipolar oscillating pulse train or a bipolar oscillating pulse train. The electric field strength can be 0.2 kV/cm to 20 kV/cm. The pulse length can be ten μs to 100 ms. There can be one to one hundred pulses. Of course, the waveform, electric field strength and pulse duration are also dependent upon the type of cells and the type of molecules that are to enter the cells via electroporation.
- The various parameters including electric field strengths required for the electroporation of any known cell is generally available from the many research papers reporting on the subject, as well as from a database maintained by Genetronics, Inc., San Diego, Calif., assignee of the subject application. The electric fields needed for in vivo cell electroporation, such as ECT, are similar in amplitude to the fields required for cells in vitro. These are in the range of from 100 V/cm to several kV/cm. This has been verified by the inventors own experiments and those of others reported in scientific publications. The first in vivo application of pulsed electric fields in the chemotherapy field to treat tumors was reported in 1987 by Okino in Japan.
- Pulse generators for carrying out the procedures described herein are and have been available on the market for a number of years. One suitable signal generator is the ELECTRO CELL
MANIPULATOR Model ECM 600 commercially available from GENETRONICS, INC. of San Diego, Calif., U.S.A. TheECM 600 signal generator generates a pulse from the complete discharge of a capacitor which results in an exponentially decaying waveform. The electric signal generated by this signal generator is characterized by a fast rise time and an exponential tail. In the signal generator, the electroporation pulse length is set by selecting one of ten timing resistors marked R1 through R10. They are active in both High Voltage Mode (HVM) (capacitance fixed at fifty microfarads) and Low Voltage Mode (LVM) (with a capacitance range from 25 to 3,175 microfarads). - The
ECM 600 signal generator has a control knob that permits the adjustment of the amplitude of the set charging voltage applied to the internal capacitors from 50 to 500 volts in LVM and from 0.05 to 2.5 kV in the HVM. The amplitude of the electrical signal is shown on a display incorporated into theECM 600 signal generator. This device further includes a plurality of push button switches for controlling pulse length, in the Low VM mode, by a simultaneous combination of resistors parallel to the output and a bank of seven selectable additive capacitors. - The
ECM 600 signal generator also includes a single automatic charge and pulse push button. This button may be depressed to initiate both charging of the internal capacitors to the set voltage and to deliver a pulse to the outside electrodes in an automatic cycle that takes less than five seconds. The manual button may be sequentially pressed to repeatedly apply the predetermined electric field. - Preferably, the therapeutic method of the invention utilizes a square wave pulse electroporation system. For example, the ElectroSquarePorator (T820), also available from GENETRONICS, INC., can be used.
- Square wave electroporation systems deliver controlled electric pulses that rise quickly to a set voltage, stay at that level for a set length of time (pulse length), and then quickly drop to zero. This type of system yields better transformation efficiency for the electroporation of plant protoplast and mammalian cell lines than an exponential decay system.
- The ElectroSquarePorator (T820) is the first commercially available square wave electropomtion system capable of generating up to 3000 volts. The pulse length can be adjusted from 5 μsec to 99 msec. The square wave electroporation pulses have a gentler effect on the cells which results in higher cell viability.
- The T820 ElectroSquarePorator is active in both the High Voltage Mode (HVM) (100-3000 volts) and the Low Voltage Mode (LVM) (50-500 volts). The pulse length for LVM is about 0.3 to 99 msec and for HVM, 5 to 99 μsec. The T820 has multiple pulsing capability from about 1 to 99 pulses.
- Mir and others have used square wave pulses for electrochemotherapy, which allows the insertion of chemotherapeutic agents into cancerous tumors. Mice were injected with a low dose of bleomycin. The cancerous tumors were then electroporated resulting in the reduction or complete remission of the tumors (Mir, L. M., Eur. J. Cancer, 27(1): 68, 1991).
- Saunders has compared the square wave with exponential decay pulses in the electroporation of plant protoplast. Square wave electroporation produced higher transformation efficiency than the exponential decay pulses. He also reported that the optimization of electroporation parameters is much easier with square wave pulses since sufficient transformation efficiency can be produced over a larger range of voltages (Saunders, Guide to Electroporation and Electrofusion, pp. 227-247, 1991).
- The therapeutic method of the invention includes electrotherapy, also referred to herein as electroporation-mediated therapy, using the apparatus of the invention for the delivery of macromolecules to a cell or tissue. As described earlier, the term “macromolecule” or “molecule” as used herein refers to drugs (e.g., chemotherapeutic agents), nucleic acids (e.g., polynucleotides), peptides and polypeptides, including antibodies. The term polynucleotides include DNA, cDNA and RNA sequences.
- Drugs contemplated for use in the method of the invention are typically chemotherapeutic agents having an antitumor or cytotoxic effect. Such drugs or agents include bleomycin, neocarcinostatin, suramin, and cisplatin. Other chemotherapeutic agents will be known to those of skill in the art (see for example The Merck Index). The chemical composition of the agent will dictate the most appropriate time to administer the agent in relation to the administration of the electric pulse. For example, while not wanting to be bound by a particular theory, it is believed that a drug having a low isoelectric point (e.g., neocarcinostatin, IEP=3.78), would likely be more effective if administered post-electroporation in order to avoid electrostatic interaction of the highly charged drug within the field. Further, such drugs as bleomycin, which have a very negative log P, (P being the partition coefficient between octanol and water), are very large in size (MW=1400), and are hydrophilic, thereby associating closely with the lipid membrane, diffuse very slowly into a tumor cell and are typically administered prior to or substantially simultaneous with the electric pulse. Electroporation facilitates entry of bleomycin or other similar drugs into the tumor cell by creating pores in the cell membrane.
- It may be desirable to modulate the expression of a gene in a cell by the introduction of a molecule by the method of the invention. The term “modulate” envisions the suppression of expression of a gene when it is over-expressed, or augmentation of expression when it is underexpressed. Where a cell proliferative disorder is associated with the expression of a gene, nucleic acid sequences that interfere with the gene's expression at the translational level can be used. This approach utilizes, for example, antisense nucleic acid, ribozymes, or triplex agents to block transcription or translation of a specific mRNA, either by masking that mRNA with an antisense nucleic acid or triplex agent, or by cleaving it with a ribozyme.
- Antisense nucleic acids are DNA or RNA molecules that are complementary to at least a portion of a specific mRNA molecule (Weintraub, Scientific American, 262: 40, 1990). In the cell, the antisense nucleic acids hybridize to the corresponding mRNA, forming a double-stranded molecule. The antisense nucleic acids interfere with the translation of the mRNA, since the cell will not translate a mRNA that is double-stranded. Antisense oligomers of about 15 nucleotides are preferred, since they are easily synthesized and are less likely to cause problems than larger molecules when introduced into the target cell. The use of antisense methods to inhiiit the in vitro translation of genes is well known in the art (Marcus-Sakura, Anal. Biochem., 172: 289, 1988).
- Use of an oligonucleotide to stall transcription is known as the triplex strategy since the oligomer winds around double-helical DNA, forming a three-strand helix. Therefore, these triplex compounds can be designed to recognize a unique site on a chosen gene (Maher, et al., Antisense Res. and Dev., 1(3): 227, 1991; Helene, C., Anticancer Drug Design, 6(6): 569, 1991).
- Ribozymes are RNA molecules possessing the ability to specifically cleave other singles-tranded RNA in a manner analogous to DNA restriction endonucleases. Through the modification of nucleotide sequences which encode these RNAs, it is possible to engineer molecules that recognize specific nucleotide sequences in an RNA molecule and cleave it (Cech, J. Amer. Med. Assn., 260: 3030, 1988). A major advantage of this approach is that, because they are sequence-specific, only mRNAs with particular sequences are inactivated.
- There are two basic types of ribozymes namely, tetrahymena-type (Hasselhoff, Nature, 334: 585, 1988) and “hammerhead”-type. Tetrahymena-type ribozymes recognize sequences which are four bases in length, while “hammerhead”-type ribozymes recognize base sequences 11-18 bases in length. The longer the recognition sequence, the greater the likelihood that the sequence will occur exclusively in the target mRNA species. Consequently, hammerhead-type ribozymes are preferable to tetrahymena-type ribozymes for inactivating a specific mRNA species and 18-based recognition sequences are preferable to shorter recognition sequences.
- The present invention also provides gene therapy for the treatment of cell proliferative or immunologic disorders mediated by a particular gene or absence thereof. Such therapy would achieve its therapeutic effect by introduction of a specific sense or antisense polynucleotide into cells having the disorder. Delivery of polynucleotides can be achieved using a recombinant expression vector such as a chimeric virus, or the polynucleotide can be delivered as “naked” DNA for example.
- Various viral vectors which can be utilized for gene therapy as taught herein include adenovirus, herpes virus, vaccinia, or, preferably, an RNA virus such as a retrovirus. Preferably, the retroviral vector is a derivative of a murine or avian retrovirus. Examples of retroviral vectors in which a single foreign gene can be inserted include, but are not limited to: Moloney murine leukemia virus (MoMuLV), Harvey murine sarcoma virus (HaMuSV), murine mammary tumor virus (MuMTV), and Rous Sarcoma Virus (RSV). When the subject is a human, a vector such as the gibbon ape leukemia virus (GALV) can be utilized. A number of additional retroviral vectors can incorporate multiple genes. All of these vectors can transfer or incorporate a gene for a selectable marker so that transduced cells can be identified and generated.
- Therapeutic peptides or polypeptides may also be included in the therapeutic method of the invention. For example, immunomodulatory agents and other biological response modifiers can be administered for incorporation by a cell. The term “biological response modifiers” is meant to encompass substances which are involved in modifying the immune response. Examples of immune response modifiers include such compounds as lymphokines. Lymphokines include tumor necrosis factor,
interleukins - Also included are polynucleotides which encode metabolic enzymes and proteins, including antiangiogenesis compounds, e.g., Factor VIII or Factor IX.
- The macromolecule of the invention also includes antibody molecules. The term “antibody” as used herein is meant to include intact molecules as well as fragments thereof, such as Fab and F(ab′)2.
- Administration of a drug, polynucleotide or polypeptide, in the method of the invention can be, for example, parenterally by injection, rapid infusion, nasopharyngeal absorption, dermal absorption, and orally. In the case of a tumor, for example, a chemotherapeutic or other agent can be administered locally, systemically or directly injected into the tumor. When a drug, for example, is administered directly into the tumor, it is advantageous to inject the drug in a “fanning” manner. The term “fanning” refers to administering the drug by changing the direction of the needle as the drug is being injected or by multiple injections in multiple directions like opening up of a hand fan, rather than as a bolus, in order to provide a greater distribution of drug throughout the tumor. As compared with a volume that is typically used in the art, it is desirable to increase the volume of the drug-containing solution, when the drug is administered (e.g., injected) intratumorally, in order to insure adequate distribution of the drug throughout the tumor. For example, in the EXAMPLES herein, one of skill in the art typically injects 50 μl of drug-containing solution, however, the results are greatly improved by increasing the volume to 150 μl. Preferably, the injection should be done very slowly and at the periphery rather than at the center of the tumor where the intertitial pressure is very high.
- Preferably, the molecule is administered substantially contemporaneously with the electroporation treatment. The term “substantially contemporaneously” means that the molecule and the electroporation treatment are administered reasonably close together with respect to time. The administration of the molecule or therapeutic agent can at any interval, depending upon such factors, for example, as the nature of the tumor, the condition of the patient, the size and chemical characteristics of the molecule and half-life of the molecule.
- Preparations for parenteral administration include sterile or aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Carriers for occlusive dressings can be used to increase skin permeability and enhance antigen absorption. Liquid dosage forms for oral administration may generally comprise a liposome solution containing the liquid dosage form. Suitable forms for suspending the liposomes include emulsions, suspensions, solutions, syrups, and elixirs containing inert diluents commonly used in the art, such as purified water. Besides the inert diluents, such compositions can also include adjuvants, wetting agents, emulsifying and suspending agents. Further, vasoconstrictor agents can be used to keep the therapeutic agent localized prior to pulsing.
- Any cell can be treated by the method of the invention. The illustrative examples provided herein demonstrate the use of the method of the invention for the treatment of tumor cells, e.g., pancreas and lung. Other cell proliferative disorders are amenable to treatment by the electroporation method of the invention. The term “cell proliferative disorder” denotes malignant as well as non-malignant cell populations which often appear to differ from the surrounding tissue both morphologically and genotypically. Malignant cells (i.e., tumors or cancer) develop as a result of a multi-step process. The method of the invention is useful in treating malignancies or other disorders of the various organ systems, particularly, for example, cells in the pancreas and lung, and also including cells of heart, kidney, muscle, breast, colon, prostate, thymus, testis, and ovary. Preferably the subject is human.
- The following examples are intended to illustrate but not limit the invention. While they are typical of those that might be used, other procedures known to those skilled in the art may alternatively be used.
- The following examples illustrate the use of electrochemotherapy (ECT) of a poorly differentiated human pancreatic tumor (Panc-3) xenografted subcutaneously on the left flank of nude mice. The single treatment procedure involved injection of bleomycin (0.5 units in 0.15 ml saline) intratumorally, using farming, as described herein followed by application of six square wave electrical pulses, ten minutes later, using proprietary needle array electrodes arranged along the circumference of a
circle 1 cm in diameter. Needle array of variable diameters (e.g., 0.5 cm, 0.75 cm and 1.5 cm can also be used to accommodate tumors of various sizes. Stoppers of various heights can be inserted at the center of the array to make the penetration depth of the needles into the tumor variable. A built-in mechanism allowed switching of electrodes for maximum coverage of the tumor by the pulsed field. The electrical parameters were: 1300 V/cm and 6×99 μs pulses spaced at 1 sec interval. - Results showed severe necrosis and edema in nearly all the mice at the treatment site. While there was a substantial reduction in the tumor volume (after a slight initial increase due to edema) of the mice in the treated group (D+E+; D=Drug, E=Electrical field), those in the control group (D+E−) increased dramatically. Nearly complete tumor regression was observed in 90% of the mice treated by ECT after 28 days. No response was seen in 10% of the mice. A complete regression with no palpable tumor has been observed in 60% of the cases 77 days after the initial treatment. However, there was tumor regrowth in 20% of the
mice 35 days after treatment but at a much slower growth rate compared to the control. This observation has been linked to incomplete treatment of large primary tumors where the needle depth was lower than the Z dimension of the tumor. Histological analysis of tumor samples showed necrotic tumor cell ghosts in D+E+group compared to a mixture of viable and necrotic cells in D+E-group. Preliminary studies with human non-small cell lung cancer (NSCLC) tumors xenografted onto nude mice have also shown very encouraging results with ECT treatment with bleomycin. - The tumor cell line Pant-3, a poorly differentiated adenocarcinoma cell line of the pancreas, was supplied by Anticancer, Inc., San Diego. For ECT experiments, tissue taken from the stock mice, where the tumor line was maintained, was thawed and cut into very small pieces about 1 mm each, and 8-10 pieces were surgically xenografted in a subcutaneous sac made in left flank of nude mice, and then closed with 6.0 surgical suture. After the average tumor size reached about 5 mm, mice with palpable tumors were divided randomly, 10 mice for control group (D+E−; D=Drug, E=Electric field) and 10 mice for ECT treatment, namely bleomycin injection followed by pulsing (D+E+) from a BTX Square Wave T820 Generator. The tumor dimensions were measured and the tumor volume calculated using the formula:
(II/6)×a×b×c
where a, b, and c are, respectively, the length, width and thickness of the tumor. 0.5 units Bleomycin (Sigma Chemicals) was dissolved in 0.15 ml of 0.9% NaCl and was injected in each mice intratumorally by fanning for both the control (D+E−) and the treated (D+E+) groups. Ten minutes after the injection, each mouse in the D+E+group was pulsed from a BTX T820 square wave electroporator with a set of needle array electrodes as described in the present invention. Electrical parameters used were as follows: field strength 1300 V/cm, 6 pulses of 99 μs each, at 1 sec interval. - The mice were monitored every day for mortality and any signs of a diseased state were noted. The tumor dimensions were measured at regular intervals and tumor growth regression/progression monitored. Another set of nude mice with xenografts of non-small cell lung cancer line was also treated by the same procedure as for the Panc-3 tumors.
-
FIGS. 10 a and 10 b show the analysis of the tumor volume determined over a 43 day period after ECT using bleomycin for the Panc-3 tumors. There was a dramatic difference between the untreated and treated mice in terms of tumor volume. There was essentially no detectable tumor after approximately 24 days of treatment. The results ofFIG. 10 are also summarized in Table 1 below. An illustration of the actual regression of the tumor is shown inFIG. 11 .TABLE 1 ELECTROCHEMOTHERAPY OF PANC-3 TUMORS IN NUDE MICE Tumor Tumor Tumor Tumor Days after volume volume volume volume treatment (mm3) C1 (mm3) C2 (mm3) T1 (mm3) T2 0 138.746 148.94 123.11 178.37 1 206.979 179.82 210.95 252.72 8 394.786 451.787 104.55 211.11 15 557.349 798.919 113.21 226.966 18 939.582 881.752 161.73 246.91 24 1391.057 1406.98 41.56 47.2228 28 1628.631 1474.21 0 0 35 2619.765 2330.31 0 0 38 2908.912 2333.967 0 0 43 3708.571 5381.759 0 0 Cell Line: poorly differentiated human pancreatic tumor (panc3) Mouse model: nude mouse Transplant: subcutaneous xenograft Control mice: C1 and C2 Treated mice: T1 and T2 - The Panc-3 experiment was repeated using a non-small cell lung cancer cell line (NSCLC), 177 (Anticancer, San Diego, Calif.). The results were similar to that found with bleomycin and Panc-3 as shown in
FIGS. 12 a and 12 b. In one experiment, a tumor that had recurred was retreated at day 27 (FIG. 13 ) and after 7 days, there was no evidence of tumor. - The Panc-3 and NSCLC models were utilized with the drug neocarcinostatin (NCS) following the same procedures as outlined above. As shown in
FIGS. 14 a and 14 b, pre-pulse dosing with NCS in a manner similar to that used for the bleomycin studies, was not effective in reducing tumor size at all. It was believed that due to the low isoelectric point of NCS, electrostatic interaction prevented the drug from entering the tumor cell. Therefore, the experiment was repeated by pulsing first and injecting NCS post-pulse. -
FIG. 14 c shows the initial tumor volume (I) as compared to the final tumor volume (F) atday 13 for 7 mice treated (Mouse ID 1-7). In several of the mice (ID FIG. 14 d, when a separate group of 5 mice were examined at day 23, all mice showed a marked reduction in tumor volume. - A comparison of
FIGS. 14 a and b with 14 c and d indicated that post-pulse with NCS was more effective than pre-pulse administration for NCS. - The present Examples illustrate that a poorly differentiated Pancreatic cancer (Panc-3) and Non-small cell lung cancer (NSCLC) xenografted subcutaneously onto nude mice can be effectively treated by the electrochemotherapy protocol using bleomycin or NCS and needle array electrodes. Other similar chemotherapeutic agents can also be effective using the method of the invention.
- The results show a complete regression of Panc-3 tumors was achieved in 60% of the treated group with no palpable tumor seen even 77 days after the single treatment. Partial regression (80% reduction in tumor volume) was observed in 30% of cases, while only 10% did not respond (Table 2).
- Histological studies clearly showed severe necrosis of the tumor region for the group subjected to ECT whereas no necrosis was apparent in the control group. Intratumoral drug injection with larger volume of bleomycin, combined with fanning to maximize uniform drug distribution throughout the tumor volume, was found to be very effective as compared to the conventional mode of injecting the drug prior to pulsing.
TABLE 2 Electrochemotherapv of Panc-3 with Bleomycin Days after treatment 28 35 57 77 CR (100%) 6 6 6 6 PR (80%) 3 NR (%) 1 1 1 1 Death 2* Tumor regrowth 2 Retreatment 2 Histology 1
Number of mice treated: 10
CR: Complete Regression
PR: Partial Regression
NR: No Response
*1 mice died afterretreatment 1 mice died after 64 days survival
- Although the invention has been described with reference to the presently preferred embodiment, it should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the following claims.
Claims (36)
1. canceled
2. A method of electroporating a portion of the body of a patient to introduce molecules into tissues therein, comprising:
a. providing an array of multiple opposed pairs of electrodes connected to a generator, wherein at least two pairs of electrodes are activated simultaneously, at least one of said pairs of electrodes having a needle configuration for penetrating tissue;
b. inserting a first pair of said needle electrodes, into selected tissue for introducing molecules into the tissue;
c. positioning a second pair of electrodes of said array of electrodes in conductive relation to said selected tissue so that said tissue is between said first and second opposed pairs of electrodes; and
d. applying electric pulses to at least two different pairs of electrodes to generate an electric field of sufficient strength to cause in vivo electroporation of the tissue.
3. A method for the delivery of molecules to a predetermined tissue of a subject, comprising:
a. providing an array of electrodes comprising at least two pairs of opposed electrodes, wherein at least one of said electrodes has a needle configuration for penetrating said tissue;
b. contacting said tissue with said array such that the electrode(s) penetrate said tissue;
C. administering said molecules to said tissue; and
d. applying at least one electric pulse simultaneously to at least two of the pairs of electrodes sufficient to electroporate cells of said tissue and thereby allow said molecules to be delivered to said tissue.
4. A method according to claim 3 , wherein the array comprises at least three pairs of opposed electrodes and at least one of said pairs is not pulsed when at least two of the pairs of electrodes are pulsed simultaneously.
5. A method according to claim 3 , wherein the molecules are selected from the group consisting of a chemotherapeutic agent, a polynucleotide, and a polypeptide.
6. A method according to claim 5 , wherein the chemotherapeutic agent is bleomycin.
7. A method according to claim 2 , wherein the molecules are administered by a method selected from the group consisting of intratumoral, systemic, and local administration.
8. A method according to claim 2 , wherein the predetermined tissue is selected from the group consisting of pancreas, lung, heart, kidney, muscle, breast, colon, prostate, thymus, testis, and ovary.
9. A method for the delivery of molecules to a predetermined tissue of a subject, comprising:
a. providing an array of electrodes comprising at least two pairs of opposed electrodes, wherein at least one of said electrodes has a needle configuration for penetrating said tissue;
b. contacting said tissue with said array such that the electrode(s) penetrate said tissue;
c. administering said molecules to said tissue;
d. applying at least one electric pulse simultaneously to at least two of the pairs of opposed electrodes sufficient to electroporate cells of said tissue using an electric field of predefined strength and thereby allow said molecules to be delivered to said tissue.
10. A method according to claim 9 , wherein the electric field of predefined strength is created by delivering electric pulse(s) of a voltage suitable to generate said electric field.
11. A method according to claim 10 , wherein the voltage is determined based on the distance between the electrodes of the electrode pair to be energized.
12. A method according to claim 9 , wherein the array comprises at least three pairs of opposed electrodes and at least one of said pairs is not pulsed when at least two of the pairs of electrodes are pulsed simultaneously.
13. A method according to claim 9 , wherein the molecules are selected from the group consisting of a chemotherapeutic agent, a polynucleotide and a polypeptide.
14. A method according to claim 9 , wherein the molecules are introduced by a method selected from the group consisting of intratumoral, systemic, and local administration.
15. A method according to claim 13 , wherein the chemotherapeutic agent is bleomycin.
16. A method according to claim 9 , wherein the tissue is selected from the group consisting of pancreas, lung, heart, kidney, muscle, breast, colon, prostate, thymus, testis, and ovary.
17. A method according to claim 8 , wherein the electric field of predefined strength has a field strength of from about 0.2 kV/cm to about 20 kV/cm.
18. A method according to claim 8 , wherein the electrode array is in a configuration selected from the group consisting of a substantially square, rectangular, and circular pattern.
19. A method for the delivery of molecules to a predetermined tissue of a subject, comprising:
a. providing an electrode apparatus for the application of at least one electric pulse, wherein said electrode apparatus comprises:
i. at least two pairs of needles for penetrating said predetermined tissue, wherein each needle has a lumen for insertion of an electrode;
ii. at least two pairs of electrodes, wherein each electrode is configured for insertion into the tissue through the lumen of one of said needles; and
iii. a power generator to apply an electric potential of sufficient strength across at least two of the pairs of the electrodes to generate an electric field for electroporation of cells of the tissue; and
b. applying at least one electric pulse simultaneously to at least two of the pairs of electrodes sufficient to electroporate cells of said tissue and thereby allow said molecules to be delivered to said tissue.
20. A method according to claim 19 , wherein the array comprises at least three pairs of opposed electrodes and at least one of said pairs is not pulsed when at least two of the pairs of electrodes are pulsed simultaneously.
21. A method according to claim 19 , wherein said needles are tubular.
22. A method according to claim 19 , wherein said needles are removed and the electrodes are left in said tissue.
23. A method according to claim 19 , wherein said needles are nonconductive.
24. A method according to claim 19 , wherein each of the electrodes comprises an elongated insulated conductor with a conductive tip at its distal end.
25. A method according to claim 19 , wherein the needles are connected to a source of molecules and are used to inject a solution comprising said molecules and a carrier into the tissue.
26. A method according to claim 19 , wherein the electrode apparatus produces electrical pulses between electrodes according to a set of predetermined electrode configurations.
27. A method according to claim 19 , wherein the electrode apparatus further comprises an identification circuit to determine the number of electrodes in the electrode apparatus and desired electrical signal parameters for the application of one or more electric pulses.
28. A method according to claim 19 , wherein the power generator includes a control module that controls at least one electrical treatment parameter selected from the group consisting of an electrode voltage set point, pulse length, pulse shape, pulse number, and an electrode switching sequence.
29. A method according to claim 28 , wherein the control module directs the power generator to generate at least one electric pulse having a voltage that depends on a spacing of the electrodes in the electrode apparatus.
30. A method according to claim 28 , wherein the control module directs the power generator to generate at least one electric pulse according to the number of electrodes in the electrode apparatus.
31. A method according to claim 19 , wherein electric field strength produces by the pulse(s) between the electrodes ranges from about 10 V/cm to about 1300 V/cm.
32. A method according to claim 19 , wherein each pulse produced by the power generator has a pulse width from about 10 microsecond to about 100 millisecond.
33. A method according to claim 19 , wherein at least one needle in the electrode apparatus is configured for transit of a solution.
34. A method according to claim 19 , wherein each electrode comprises a base portion that makes electrical contact with the electrode apparatus and a distal tip portion that is exposed to deliver electricity to tissue, wherein the electrode is covered with a layer of electrically insulating material between the base portion and the distal tip portion.
35. A method for the delivery of molecules to a predetermined tissue of a subject, comprising:
a. providing an electrode apparatus for the application of at least one electric pulse, wherein said electrode apparatus comprises:
i. at least two pairs of needle electrodes for penetrating said predetermined tissue, wherein at least one of said needle electrodes is used to deliver a solution containing said molecules to said tissue, and wherein at least two pairs of said needle electrodes is used to deliver at least one electric impulse; and
ii. a power generator to apply an electric potential of sufficient strength across at least two of the pairs of the electrodes to generate an electric field for electroporation of cells of the tissue; and
b. applying at least one electric pulse simultaneously to at least two of the pairs of electrodes sufficient to electroporate cells of said tissue and thereby allow said molecules to be delivered to said tissue.
36. A method according to claim 35 , wherein the electrode apparatus comprises at least three pairs of opposed electrodes and at least one of said pairs is not pulsed when at least two of the pairs of electrodes are pulsed simultaneously.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/783,161 US20050192542A1 (en) | 1993-04-01 | 2004-02-20 | Method of treatment using electroporation mediated delivery of drugs and genes |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/042,039 US5439440A (en) | 1993-04-01 | 1993-04-01 | Electroporation system with voltage control feedback for clinical applications |
US08/467,566 US5702359A (en) | 1995-06-06 | 1995-06-06 | Needle electrodes for mediated delivery of drugs and genes |
US10/213,514 US6763264B2 (en) | 1993-04-01 | 2002-08-06 | Method of treatment using electroporation mediated delivery of drugs and genes |
US10/783,161 US20050192542A1 (en) | 1993-04-01 | 2004-02-20 | Method of treatment using electroporation mediated delivery of drugs and genes |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/467,566 Continuation-In-Part US5702359A (en) | 1993-04-01 | 1995-06-06 | Needle electrodes for mediated delivery of drugs and genes |
US10/213,514 Continuation US6763264B2 (en) | 1993-04-01 | 2002-08-06 | Method of treatment using electroporation mediated delivery of drugs and genes |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050192542A1 true US20050192542A1 (en) | 2005-09-01 |
Family
ID=23856229
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/467,566 Expired - Lifetime US5702359A (en) | 1993-04-01 | 1995-06-06 | Needle electrodes for mediated delivery of drugs and genes |
US10/783,161 Abandoned US20050192542A1 (en) | 1993-04-01 | 2004-02-20 | Method of treatment using electroporation mediated delivery of drugs and genes |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/467,566 Expired - Lifetime US5702359A (en) | 1993-04-01 | 1995-06-06 | Needle electrodes for mediated delivery of drugs and genes |
Country Status (2)
Country | Link |
---|---|
US (2) | US5702359A (en) |
RU (1) | RU2168337C2 (en) |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7190997B1 (en) * | 1999-06-04 | 2007-03-13 | Impulse Dynamics Nv | Drug delivery device |
US20070185540A1 (en) * | 1997-07-16 | 2007-08-09 | Shlomo Ben-Haim | Smooth Muscle Controller |
US20090131994A1 (en) * | 2006-04-07 | 2009-05-21 | University Of South Florida | Passive Electric Field Focus System for In Vivo and In Vitro Applications |
US7840262B2 (en) | 2003-03-10 | 2010-11-23 | Impulse Dynamics Nv | Apparatus and method for delivering electrical signals to modify gene expression in cardiac tissue |
US8244371B2 (en) | 2005-03-18 | 2012-08-14 | Metacure Limited | Pancreas lead |
US8260416B2 (en) | 1996-01-08 | 2012-09-04 | Impulse Dynamics, N.V. | Electrical muscle controller |
US8321013B2 (en) | 1996-01-08 | 2012-11-27 | Impulse Dynamics, N.V. | Electrical muscle controller and pacing with hemodynamic enhancement |
US8352031B2 (en) | 2004-03-10 | 2013-01-08 | Impulse Dynamics Nv | Protein activity modification |
US8548583B2 (en) | 2004-03-10 | 2013-10-01 | Impulse Dynamics Nv | Protein activity modification |
US8655444B2 (en) | 1996-01-08 | 2014-02-18 | Impulse Dynamics, N.V. | Electrical muscle controller |
US8666495B2 (en) | 1999-03-05 | 2014-03-04 | Metacure Limited | Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar |
US8700161B2 (en) | 1999-03-05 | 2014-04-15 | Metacure Limited | Blood glucose level control |
US8792985B2 (en) | 2003-07-21 | 2014-07-29 | Metacure Limited | Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar |
US8825152B2 (en) | 1996-01-08 | 2014-09-02 | Impulse Dynamics, N.V. | Modulation of intracellular calcium concentration using non-excitatory electrical signals applied to the tissue |
US8934975B2 (en) | 2010-02-01 | 2015-01-13 | Metacure Limited | Gastrointestinal electrical therapy |
US9101765B2 (en) | 1999-03-05 | 2015-08-11 | Metacure Limited | Non-immediate effects of therapy |
US9289618B1 (en) | 1996-01-08 | 2016-03-22 | Impulse Dynamics Nv | Electrical muscle controller |
US9457183B2 (en) | 2011-06-15 | 2016-10-04 | Tripep Ab | Injection needle and device |
US9713723B2 (en) | 1996-01-11 | 2017-07-25 | Impulse Dynamics Nv | Signal delivery through the right ventricular septum |
US9931503B2 (en) | 2003-03-10 | 2018-04-03 | Impulse Dynamics Nv | Protein activity modification |
US11439815B2 (en) | 2003-03-10 | 2022-09-13 | Impulse Dynamics Nv | Protein activity modification |
US11779768B2 (en) | 2004-03-10 | 2023-10-10 | Impulse Dynamics Nv | Protein activity modification |
WO2023224829A1 (en) * | 2022-05-16 | 2023-11-23 | Vector Surgical, Llc | Intracellular treatment device and methods of use thereof |
Families Citing this family (221)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5993434A (en) * | 1993-04-01 | 1999-11-30 | Genetronics, Inc. | Method of treatment using electroporation mediated delivery of drugs and genes |
US5702359A (en) * | 1995-06-06 | 1997-12-30 | Genetronics, Inc. | Needle electrodes for mediated delivery of drugs and genes |
IL108775A (en) * | 1994-02-25 | 2003-09-17 | Univ Ramot | Method for efficient incorporation of molecules into cells |
US6322548B1 (en) | 1995-05-10 | 2001-11-27 | Eclipse Surgical Technologies | Delivery catheter system for heart chamber |
US6041252A (en) * | 1995-06-07 | 2000-03-21 | Ichor Medical Systems Inc. | Drug delivery system and method |
US6230051B1 (en) * | 1996-06-18 | 2001-05-08 | Alza Corporation | Device for enhancing transdermal agent delivery or sampling |
US5983136A (en) * | 1996-09-17 | 1999-11-09 | Deka Products Limited Partnership | System for delivery of drugs by transport |
KR100427786B1 (en) * | 1997-04-03 | 2004-04-30 | 일렉트로우펙트 에이에스 | Method and device for introducing pharmaceutical drugs and nucleic acids into skeletal muscle |
US6261281B1 (en) * | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
US5873849A (en) * | 1997-04-24 | 1999-02-23 | Ichor Medical Systems, Inc. | Electrodes and electrode arrays for generating electroporation inducing electrical fields |
DE69826124T3 (en) | 1997-06-30 | 2007-10-11 | Institut Gustave Roussy | ADMINISTRATION OF NUCLEIC ACID IN CROSS-LINKED MUSCLES |
KR20010020570A (en) | 1997-06-30 | 2001-03-15 | 자끄 사비나 | Improved method for transferring nucleic acid into multicelled eukaryotic organism cells and combination therefor |
US6096037A (en) | 1997-07-29 | 2000-08-01 | Medtronic, Inc. | Tissue sealing electrosurgery device and methods of sealing tissue |
US6216034B1 (en) | 1997-08-01 | 2001-04-10 | Genetronics, Inc. | Method of programming an array of needle electrodes for electroporation therapy of tissue |
US6055453A (en) * | 1997-08-01 | 2000-04-25 | Genetronics, Inc. | Apparatus for addressing needle array electrodes for electroporation therapy |
US6241701B1 (en) | 1997-08-01 | 2001-06-05 | Genetronics, Inc. | Apparatus for electroporation mediated delivery of drugs and genes |
WO2003046171A1 (en) * | 2001-11-27 | 2003-06-05 | Cellectricon Ab | A method for combined sequential agent delivery and electroporation for cell structures and use thereof |
SE9704076D0 (en) | 1997-11-06 | 1997-11-06 | Holdingbolaget Vid Goeteborgs | Method for permeabilization of cell structures and use thereof |
US6356783B1 (en) | 1997-11-20 | 2002-03-12 | David R. Hubbard, Jr. | Multi-electrode and needle injection device for diagnosis and treatment of muscle injury and pain |
WO1999042156A1 (en) | 1998-02-24 | 1999-08-26 | Boston Scientific Limited | High flow rate dialysis catheters and related methods |
US6027488A (en) | 1998-06-03 | 2000-02-22 | Genetronics, Inc. | Flow-through electroporation system for ex vivo gene therapy |
US20040229363A1 (en) * | 1998-06-24 | 2004-11-18 | Ed Nolan | High efficiency transfection based on low electric field strength, long pulse length |
ES2291035T3 (en) * | 1998-06-26 | 2008-02-16 | Genetronics, Inc. | SYNERGISM OF DYNAMIC EFFECTS AND ELECTROPERMEABILIZATION ON CELL VITALITY AS A NEW CITOTOXIC AGENT. |
EP2428249B1 (en) * | 1998-07-13 | 2015-10-07 | Inovio Pharmaceuticals, Inc. | Skin and muscle-targeted gene therapy by pulsed electrical field |
US6678556B1 (en) | 1998-07-13 | 2004-01-13 | Genetronics, Inc. | Electrical field therapy with reduced histopathological change in muscle |
CA2337129A1 (en) | 1998-07-13 | 2000-01-20 | Genetronics, Inc. | Method and apparatus for electrically assisted topical delivery of agents for cosmetic applications |
US7922709B2 (en) | 1998-07-13 | 2011-04-12 | Genetronics, Inc. | Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation |
EP1100580A1 (en) | 1998-07-20 | 2001-05-23 | Ichor Medical Systems, Inc. | Electroporation electrodes |
US6319901B1 (en) | 1998-10-15 | 2001-11-20 | Ichor Medical Systems, Inc. | Methods for prolonging cell membrane permeability |
US6678558B1 (en) * | 1999-03-25 | 2004-01-13 | Genetronics, Inc. | Method and apparatus for reducing electroporation-mediated muscle reaction and pain response |
EP1171189B1 (en) | 1999-03-25 | 2016-05-11 | Inovio Pharmaceuticals, Inc. | Apparatus for reducing electroporation-mediated muscle reaction and pain response |
EP1183068A4 (en) | 1999-05-10 | 2008-12-17 | Gentronics Inc | Method of electroporation-enhanced delivery of active agents |
US7171264B1 (en) * | 1999-05-10 | 2007-01-30 | Genetronics, Inc. | Intradermal delivery of active agents by needle-free injection and electroporation |
US6300108B1 (en) | 1999-07-21 | 2001-10-09 | The Regents Of The University Of California | Controlled electroporation and mass transfer across cell membranes |
US6326177B1 (en) | 1999-08-04 | 2001-12-04 | Eastern Virginia Medical School Of The Medical College Of Hampton Roads | Method and apparatus for intracellular electro-manipulation |
US6904324B2 (en) * | 1999-12-01 | 2005-06-07 | Meagan Medical, Inc. | Method and apparatus for deploying a percutaneous probe |
US6549810B1 (en) | 1999-12-01 | 2003-04-15 | Vertis Neuroscience, Inc. | Percutaneous electrical therapy system with electrode depth control |
US6493592B1 (en) | 1999-12-01 | 2002-12-10 | Vertis Neuroscience, Inc. | Percutaneous electrical therapy system with electrode position maintenance |
US6560491B1 (en) | 1999-12-01 | 2003-05-06 | Vertis Neuroscience, Inc. | Percutaneous electrical therapy system providing electrode axial support |
US6516226B1 (en) | 1999-12-01 | 2003-02-04 | Vertis Neuroscience, Inc. | Percutaneous electrical therapy system for minimizing electrode insertion discomfort |
US6549797B1 (en) | 1999-12-01 | 2003-04-15 | Vertis Neuroscience, Inc. | Electrode remover for a percutaneous electrical therapy system |
US6912424B2 (en) | 1999-12-01 | 2005-06-28 | Meagan, Medical, Inc. | Apparatus and method for coupling therapeutic and/or monitoring equipment to a patient |
US6622051B1 (en) | 1999-12-01 | 2003-09-16 | Vertis Neuroscience, Inc. | Percutaneous electrical therapy system with electrode entry angle control |
US6542780B1 (en) | 1999-12-01 | 2003-04-01 | Vertis Neuroscience, Inc. | Method and apparatus for electrically coupling a percutaneous probe |
US6556869B1 (en) | 1999-12-01 | 2003-04-29 | Vertis Neuroscience, Inc. | Electrode introducer for a percutaneous electrical therapy system |
US6539264B1 (en) | 1999-12-01 | 2003-03-25 | Vertis Neuroscience, Inc. | Percutaneous electrical therapy system with sharp point protection |
US6522927B1 (en) | 1999-12-01 | 2003-02-18 | Vertis Neuroscience, Inc. | Electrode assembly for a percutaneous electrical therapy system |
JP4566496B2 (en) | 1999-12-15 | 2010-10-20 | ユニヴァーシティ オブ サウス フロリダ | Electroporation element and electroporation method |
US6905498B2 (en) | 2000-04-27 | 2005-06-14 | Atricure Inc. | Transmural ablation device with EKG sensor and pacing electrode |
US6932811B2 (en) | 2000-04-27 | 2005-08-23 | Atricure, Inc. | Transmural ablation device with integral EKG sensor |
US20020107514A1 (en) | 2000-04-27 | 2002-08-08 | Hooven Michael D. | Transmural ablation device with parallel jaws |
US6546935B2 (en) | 2000-04-27 | 2003-04-15 | Atricure, Inc. | Method for transmural ablation |
AU6475901A (en) | 2000-05-22 | 2001-12-03 | Merck And Company Inc | System and method for assessing the performance of a pharmaceutical agent delivery system |
US7588554B2 (en) * | 2000-06-26 | 2009-09-15 | Boston Scientific Scimed, Inc. | Method and apparatus for treating ischemic tissue |
US6697670B2 (en) | 2001-08-17 | 2004-02-24 | Minnesota Medical Physics, Llc | Apparatus and method for reducing subcutaneous fat deposits by electroporation with improved comfort of patients |
US6892099B2 (en) | 2001-02-08 | 2005-05-10 | Minnesota Medical Physics, Llc | Apparatus and method for reducing subcutaneous fat deposits, virtual face lift and body sculpturing by electroporation |
US6795728B2 (en) | 2001-08-17 | 2004-09-21 | Minnesota Medical Physics, Llc | Apparatus and method for reducing subcutaneous fat deposits by electroporation |
US8251986B2 (en) | 2000-08-17 | 2012-08-28 | Angiodynamics, Inc. | Method of destroying tissue cells by eletroporation |
US7118555B2 (en) * | 2000-09-21 | 2006-10-10 | Meagan Medical, Inc. | Method and apparatus for repositioning a percutaneous probe |
US6671557B1 (en) | 2000-10-10 | 2003-12-30 | Meagan Medical, Inc. | System and method for providing percutaneous electrical therapy |
US6701190B2 (en) | 2000-10-10 | 2004-03-02 | Meagan Medical, Inc. | System and method for varying characteristics of electrical therapy |
US20040138621A1 (en) | 2003-01-14 | 2004-07-15 | Jahns Scott E. | Devices and methods for interstitial injection of biologic agents into tissue |
US7740623B2 (en) | 2001-01-13 | 2010-06-22 | Medtronic, Inc. | Devices and methods for interstitial injection of biologic agents into tissue |
WO2002072781A2 (en) * | 2001-03-13 | 2002-09-19 | University Of South Florida | Electromanipulation device and method |
US6625486B2 (en) | 2001-04-11 | 2003-09-23 | Advanced Cardiovascular Systems, Inc. | Method and apparatus for intracellular delivery of an agent |
US7127284B2 (en) * | 2001-06-11 | 2006-10-24 | Mercator Medsystems, Inc. | Electroporation microneedle and methods for its use |
US20040204669A1 (en) * | 2001-07-05 | 2004-10-14 | Hofmann Gunter A. | Apparatus for electroporation mediated delivery for drugs and genes |
USRE42016E1 (en) | 2001-08-13 | 2010-12-28 | Angiodynamics, Inc. | Apparatus and method for the treatment of benign prostatic hyperplasia |
US6994706B2 (en) * | 2001-08-13 | 2006-02-07 | Minnesota Medical Physics, Llc | Apparatus and method for treatment of benign prostatic hyperplasia |
AU2002360540A1 (en) * | 2001-12-04 | 2003-06-17 | University Of Southern California | Method for intracellular modifications within living cells using pulsed electric fields |
US7967816B2 (en) | 2002-01-25 | 2011-06-28 | Medtronic, Inc. | Fluid-assisted electrosurgical instrument with shapeable electrode |
JP2005530695A (en) * | 2002-02-15 | 2005-10-13 | ザイコス インク. | Electroporation method for introducing physiologically active substances into cells |
US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
PT1480720T (en) * | 2002-03-07 | 2018-11-23 | Inovio Pharmaceuticals Inc | Electrode assembly for constant-current electroporation |
JP2005518904A (en) | 2002-03-07 | 2005-06-30 | マーク アンド カンパニー インコーポレイテッド | Clinical syringe with electrical stimulation aspect |
US7245963B2 (en) * | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
US7218962B2 (en) * | 2002-03-29 | 2007-05-15 | Boston Scientific Scimed, Inc. | Magnetically enhanced injection catheter |
US6912417B1 (en) * | 2002-04-05 | 2005-06-28 | Ichor Medical Systmes, Inc. | Method and apparatus for delivery of therapeutic agents |
JP4499427B2 (en) | 2002-04-16 | 2010-07-07 | サイト パルス サイエンシズ、インコーポレイテッド | A method of treating biomaterials by moving electric fields and reversing electrode polarity. |
US7328064B2 (en) | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
US20040078063A1 (en) * | 2002-10-17 | 2004-04-22 | Mclaren Brian | Electrical apparatus and methods for denaturing venoms and toxins |
US7288092B2 (en) | 2003-04-23 | 2007-10-30 | Atricure, Inc. | Method and apparatus for ablating cardiac tissue with guide facility |
PL1696812T3 (en) | 2003-12-24 | 2015-12-31 | Univ California | Tissue ablation with irreversible electroporation |
US8298222B2 (en) | 2003-12-24 | 2012-10-30 | The Regents Of The University Of California | Electroporation to deliver chemotherapeutics and enhance tumor regression |
WO2005065722A2 (en) * | 2003-12-31 | 2005-07-21 | Advisys, Inc. | Reducing arthritis and lameness in subjects by growth hormone releasing hormone (ghrh) supplementation |
ATE507239T1 (en) * | 2004-01-20 | 2011-05-15 | VGX Pharmaceuticals LLC | INCREASED SECRETION/RETENTION OF GROWTH HORMONE RELEASING HORMONE (GHRH) FROM MUSCLE CELLS BY SPECIES-SPECIFIC SIGNALING PEPTIDE |
GB0402569D0 (en) * | 2004-02-05 | 2004-03-10 | Neurodan As | Nerve and/or muscle stimulation electrodes |
EP3466483A1 (en) | 2004-03-08 | 2019-04-10 | Ichor Medical Systems Inc. | Improved apparatus for electrically mediated delivery of therapeutic agents |
JP2005278480A (en) * | 2004-03-29 | 2005-10-13 | Fujitsu Ltd | Device for introducing material and tip for introducing material |
AU2005231443B2 (en) | 2004-04-01 | 2012-02-23 | The General Hospital Corporation | Method and apparatus for dermatological treatment and tissue reshaping |
US20050226991A1 (en) * | 2004-04-07 | 2005-10-13 | Hossainy Syed F | Methods for modifying balloon of a catheter assembly |
US7530980B2 (en) | 2004-04-14 | 2009-05-12 | Atricure, Inc | Bipolar transmural ablation method and apparatus |
JP4504082B2 (en) * | 2004-04-28 | 2010-07-14 | 富士通株式会社 | Liquid injection device |
EP1750608B1 (en) | 2004-06-02 | 2012-10-03 | Medtronic, Inc. | Ablation device with jaws |
EP1809336B1 (en) * | 2004-07-23 | 2008-11-12 | Advisys, Inc. | Growth hormone releasing hormone enhances the immune response induced by vaccination |
WO2006084173A1 (en) * | 2005-02-04 | 2006-08-10 | The Johns Hopkins University | Electroporation gene therapy gun system |
GB0502384D0 (en) * | 2005-02-04 | 2005-03-16 | Instrumedical Ltd | Electro-surgical needle apparatus |
US8114070B2 (en) | 2005-06-24 | 2012-02-14 | Angiodynamics, Inc. | Methods and systems for treating BPH using electroporation |
US20060293730A1 (en) | 2005-06-24 | 2006-12-28 | Boris Rubinsky | Methods and systems for treating restenosis sites using electroporation |
US7647122B2 (en) * | 2005-07-26 | 2010-01-12 | Medtronic, Inc. | Surgical needle driver |
JP2009518044A (en) * | 2005-12-07 | 2009-05-07 | ジェネトロニクス,インコーポレイティド | Variable volume electroporation chamber and method of use thereof |
US20080287857A1 (en) * | 2006-02-11 | 2008-11-20 | Rune Kjeken | Device and method for single-needle in vivo electroporation |
EP1981581B1 (en) | 2006-02-11 | 2016-04-13 | Genetronics, Inc. | Device for single-needle in vivo electroporation |
US20080045880A1 (en) * | 2006-02-11 | 2008-02-21 | Rune Kjeken | Device and method for single-needle in vivo electroporation |
CN102921102B (en) | 2006-03-03 | 2015-06-10 | 基因特伦尼克斯公司 | Device for treating microscopic tumors remaining in tissues following surgical resection |
DE602007003723D1 (en) * | 2006-06-12 | 2010-01-21 | Region Hovedstaden V Herlev Ho | ELEKTRODENEINFÜHREINRICHTUNG |
WO2008006019A2 (en) * | 2006-07-06 | 2008-01-10 | Advisys Inc. | Growth hormone releasing hormone treatment to decrease cholesterol levels |
US8142426B2 (en) | 2006-10-16 | 2012-03-27 | Syneron Medical Ltd. | Methods and devices for treating tissue |
US8007493B2 (en) | 2006-10-16 | 2011-08-30 | Syneron Medical Ltd. | Methods and devices for treating tissue |
US8273080B2 (en) | 2006-10-16 | 2012-09-25 | Syneron Medical Ltd. | Methods and devices for treating tissue |
US8133216B2 (en) | 2006-10-16 | 2012-03-13 | Syneron Medical Ltd. | Methods and devices for treating tissue |
EP2076313A4 (en) | 2006-10-16 | 2012-07-25 | Univ California | Gels with predetermined conductivity used in irreversible electroporation of tissue |
DK2066399T3 (en) | 2006-10-17 | 2019-01-21 | Inovio Pharmaceuticals Inc | Electroporation devices and methods for using them for the electroporation of cells in mammals |
US20080312647A1 (en) * | 2007-06-15 | 2008-12-18 | Primaeva Medical, Inc. | Methods and devices for treating tissue |
US8845630B2 (en) | 2007-06-15 | 2014-09-30 | Syneron Medical Ltd | Devices and methods for percutaneous energy delivery |
US20090036958A1 (en) * | 2007-08-01 | 2009-02-05 | Primaeva Medical, Inc. | Methods and devices for treating tissue |
WO2009091578A1 (en) * | 2008-01-17 | 2009-07-23 | Genetronics, Inc. | Variable current density single needle electroporation system and method |
WO2009121017A1 (en) | 2008-03-27 | 2009-10-01 | The Regents Of The University Of California | Balloon catheter for reducing restenosis via irreversible electroporation |
WO2009124312A2 (en) * | 2008-04-04 | 2009-10-08 | The Trustees Of The University Of Pennsylvania | Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same |
AU2009231598B2 (en) | 2008-04-04 | 2015-03-12 | The Trustees Of The University Of Pennsylvania | Vaccines and immunotherapeutics using IL-28 and compositions and methods of using the same |
US10272178B2 (en) | 2008-04-29 | 2019-04-30 | Virginia Tech Intellectual Properties Inc. | Methods for blood-brain barrier disruption using electrical energy |
US9198733B2 (en) | 2008-04-29 | 2015-12-01 | Virginia Tech Intellectual Properties, Inc. | Treatment planning for electroporation-based therapies |
US10117707B2 (en) | 2008-04-29 | 2018-11-06 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies |
WO2009134876A1 (en) | 2008-04-29 | 2009-11-05 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation to create tissue scaffolds |
US10702326B2 (en) | 2011-07-15 | 2020-07-07 | Virginia Tech Intellectual Properties, Inc. | Device and method for electroporation based treatment of stenosis of a tubular body part |
US11272979B2 (en) | 2008-04-29 | 2022-03-15 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies |
US10238447B2 (en) | 2008-04-29 | 2019-03-26 | Virginia Tech Intellectual Properties, Inc. | System and method for ablating a tissue site by electroporation with real-time monitoring of treatment progress |
US11254926B2 (en) | 2008-04-29 | 2022-02-22 | Virginia Tech Intellectual Properties, Inc. | Devices and methods for high frequency electroporation |
US9867652B2 (en) | 2008-04-29 | 2018-01-16 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds |
US9283051B2 (en) | 2008-04-29 | 2016-03-15 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating a treatment volume for administering electrical-energy based therapies |
US8992517B2 (en) | 2008-04-29 | 2015-03-31 | Virginia Tech Intellectual Properties Inc. | Irreversible electroporation to treat aberrant cell masses |
US10245098B2 (en) | 2008-04-29 | 2019-04-02 | Virginia Tech Intellectual Properties, Inc. | Acute blood-brain barrier disruption using electrical energy based therapy |
US8348938B2 (en) | 2008-05-06 | 2013-01-08 | Old Dominian University Research Foundation | Apparatus, systems and methods for treating a human tissue condition |
US20090281477A1 (en) | 2008-05-09 | 2009-11-12 | Angiodynamics, Inc. | Electroporation device and method |
US9173704B2 (en) | 2008-06-20 | 2015-11-03 | Angiodynamics, Inc. | Device and method for the ablation of fibrin sheath formation on a venous catheter |
US9681909B2 (en) | 2008-06-23 | 2017-06-20 | Angiodynamics, Inc. | Treatment devices and methods |
KR101054828B1 (en) | 2009-01-22 | 2011-08-05 | 신경민 | Electrode device for high frequency thermal therapy |
WO2010085765A2 (en) | 2009-01-23 | 2010-07-29 | Moshe Meir H | Therapeutic energy delivery device with rotational mechanism |
WO2010093692A2 (en) | 2009-02-10 | 2010-08-19 | Hobbs Eamonn P | Irreversible electroporation and tissue regeneration |
US11638603B2 (en) | 2009-04-09 | 2023-05-02 | Virginia Tech Intellectual Properties, Inc. | Selective modulation of intracellular effects of cells using pulsed electric fields |
WO2010118387A1 (en) | 2009-04-09 | 2010-10-14 | Virginia Tech Intellectual Properties, Inc. | Integration of very short electric pulses for minimally to noninvasive electroporation |
US11382681B2 (en) | 2009-04-09 | 2022-07-12 | Virginia Tech Intellectual Properties, Inc. | Device and methods for delivery of high frequency electrical pulses for non-thermal ablation |
USD630321S1 (en) | 2009-05-08 | 2011-01-04 | Angio Dynamics, Inc. | Probe handle |
US8903488B2 (en) | 2009-05-28 | 2014-12-02 | Angiodynamics, Inc. | System and method for synchronizing energy delivery to the cardiac rhythm |
US9895189B2 (en) | 2009-06-19 | 2018-02-20 | Angiodynamics, Inc. | Methods of sterilization and treating infection using irreversible electroporation |
EP3488837A1 (en) | 2009-07-15 | 2019-05-29 | NewSouth Innovations Pty Limited | Electroporation apparatus for providing agents to the cochlea |
WO2011032179A1 (en) | 2009-09-14 | 2011-03-17 | The Trustees Of The University Of Pennsylvania | Vaccines and immunotherapeutics comprising il-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same |
US20110118732A1 (en) | 2009-11-19 | 2011-05-19 | The Regents Of The University Of California | Controlled irreversible electroporation |
US20120076808A1 (en) | 2010-09-27 | 2012-03-29 | China Agricultural University | Combined antigen and dna vaccine for preventing and treating autoimmune diseases |
WO2012051433A2 (en) | 2010-10-13 | 2012-04-19 | Angiodynamics, Inc. | System and method for electrically ablating tissue of a patient |
WO2012088149A2 (en) | 2010-12-20 | 2012-06-28 | Virginia Tech Intellectual Properties, Inc. | High-frequency electroporation for cancer therapy |
CN102631243B (en) * | 2011-02-15 | 2014-09-17 | 成功大学 | Therapeutic device for electromagnetic thermotherapy |
KR102436439B1 (en) | 2011-06-28 | 2022-08-25 | 이노비오 파마수티컬즈, 인크. | A miniminally invasive dermal electroporation device |
US9078665B2 (en) | 2011-09-28 | 2015-07-14 | Angiodynamics, Inc. | Multiple treatment zone ablation probe |
WO2013067652A1 (en) | 2011-11-10 | 2013-05-16 | Beijing Advaccine Biotechnology Co., Ltd. | Facilitator-dna combination vaccine |
ITCO20120004A1 (en) * | 2012-02-07 | 2013-08-08 | Giuseppe Caccia | APPARATUS FOR VAGINAL AND ANAL DYNAMIC ELECTROPORATION |
US9414881B2 (en) | 2012-02-08 | 2016-08-16 | Angiodynamics, Inc. | System and method for increasing a target zone for electrical ablation |
CN103239734B (en) | 2012-02-10 | 2016-02-24 | 北京艾棣维欣生物技术有限公司 | For preventing and/or treating the vaccine of respiratory syncytial virus infection |
US9144459B2 (en) | 2012-07-19 | 2015-09-29 | Cook Medical Technologies Llc | Endoscopic ultrasound ablation needle |
AU2013358947B2 (en) | 2012-12-13 | 2016-10-20 | Inovio Pharmaceuticals, Inc. | WT1 vaccine |
WO2014194244A1 (en) | 2013-05-30 | 2014-12-04 | Duke University | Enzyme-catalyzed synthesis of site-specific and stoichiometric biomolecule-polymer conjugates |
US10392611B2 (en) | 2013-05-30 | 2019-08-27 | Duke University | Polymer conjugates having reduced antigenicity and methods of using the same |
US10364451B2 (en) | 2013-05-30 | 2019-07-30 | Duke University | Polymer conjugates having reduced antigenicity and methods of using the same |
WO2014201511A1 (en) | 2013-06-21 | 2014-12-24 | Gary David Housley | Method and apparatus for close-field electroporation |
DK3028048T3 (en) | 2013-07-31 | 2019-01-21 | Bioventures Llc | COMPOSITIONS FOR TREATMENT AND PREVENTION OF CANCER TARGETING AGAINST TUMOR-ASSOCIATED CARBOHYDRATE ANTIGEN |
CA2926025A1 (en) | 2013-10-07 | 2015-04-16 | The Trustees Of The University Of Pennsylvania | Vaccines with interleukin-33 as an adjuvant |
WO2015070027A1 (en) | 2013-11-07 | 2015-05-14 | University Of Southern California | Use of ikk epsilon inhibitors to activate nfat and t cell response |
US20160256539A1 (en) | 2013-11-14 | 2016-09-08 | The Trustees Of The University Of Pennsylvania | HIV-1 ENV DNA Vaccine Plus Protein Boost Delivered by EP Expands B- and T-Cell Response and Neutralizing |
AU2014354797C1 (en) | 2013-11-29 | 2018-02-01 | Inovio Pharmaceuticals, Inc. | MERS-CoV vaccine |
US10835595B2 (en) | 2014-01-06 | 2020-11-17 | The Trustees Of The University Of Pennsylvania | PD1 and PDL1 antibodies and vaccine combinations and use of same for immunotherapy |
US10166321B2 (en) | 2014-01-09 | 2019-01-01 | Angiodynamics, Inc. | High-flow port and infusion needle systems |
JP6751351B2 (en) | 2014-05-02 | 2020-09-02 | コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. | Device to inactivate bacteria |
CN112807074A (en) | 2014-05-12 | 2021-05-18 | 弗吉尼亚暨州立大学知识产权公司 | Electroporation system |
JP6737778B2 (en) | 2014-10-01 | 2020-08-12 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Vaccine with antigen and interleukin-21 as adjuvant |
US10694972B2 (en) | 2014-12-15 | 2020-06-30 | Virginia Tech Intellectual Properties, Inc. | Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment |
WO2016123285A1 (en) | 2015-01-29 | 2016-08-04 | The Trustees Of The University Of Pennsylvania | Checkpoint inhibitor and vaccine combinations and use of same for immunotherapy |
WO2016154530A1 (en) | 2015-03-26 | 2016-09-29 | Duke University | Targeted therapeutic agents comprising multivalent protein-biopolymer fusions |
JP6882782B2 (en) | 2015-08-04 | 2021-06-02 | デューク ユニバーシティ | Genetically encoded, essentially chaotic delivery stealth polymers and how to use them |
US11752213B2 (en) | 2015-12-21 | 2023-09-12 | Duke University | Surfaces having reduced non-specific binding and antigenicity |
US20190015520A1 (en) | 2015-12-21 | 2019-01-17 | Duke University | Polymer conjugates having reduced antigenicity and methods of using the same |
MX2018008007A (en) | 2015-12-30 | 2019-03-28 | Inovio Pharmaceuticals Inc | Electroporation device with detachable needle array with lock-out system. |
KR102535764B1 (en) | 2016-03-28 | 2023-05-30 | 아이커 메디칼 시스템스 인코포레이티드 | Apparatus for delivery of therapeutic agents |
WO2017173398A1 (en) | 2016-04-01 | 2017-10-05 | Duke University | Alpha-helical peptide nanofibers as a self-adjuvanting vaccine platform |
CN109415714A (en) | 2016-04-29 | 2019-03-01 | 艾诺奥医药品有限公司 | Enhance the delivering of medicament using chondroitinase and/or hyaluronidase in vivo |
US20170340283A1 (en) * | 2016-05-24 | 2017-11-30 | Ironwood Electronics, Inc. | Needle probe array and methods regarding same |
US11467156B2 (en) | 2016-06-01 | 2022-10-11 | Duke University | Nonfouling biosensors |
IT201600068691A1 (en) * | 2016-07-01 | 2018-01-01 | Igea S P A | HANDLING AND CONTROL SYSTEM FOR EXPANDABLE ELECTRODES OF A HANDPIECE USED IN AN ELECTRO-PORTION PROCESS |
CN109890833A (en) | 2016-09-14 | 2019-06-14 | 杜克大学 | The nanoparticle based on three block polypeptide for delivery of hydrophilic drug |
KR20190064600A (en) | 2016-09-23 | 2019-06-10 | 듀크 유니버시티 | Unstructured non-repetitive polypeptides with LCST behavior |
US10905492B2 (en) | 2016-11-17 | 2021-02-02 | Angiodynamics, Inc. | Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode |
US10376495B2 (en) | 2016-11-23 | 2019-08-13 | University Of South Florida | Small molecules that mimic or antagonize actions of granulocyte colony-stimulating-factor (G-CSF) |
KR102539625B1 (en) | 2016-12-22 | 2023-06-05 | 오하이오 스테이트 이노베이션 파운데이션 | Interpenetrating microstructures for cargo delivery based on nanochannels |
US11648200B2 (en) | 2017-01-12 | 2023-05-16 | Duke University | Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly |
US10813935B2 (en) | 2017-02-23 | 2020-10-27 | Transgenex Nanobiotech, Inc. | Methods and compositions for treating drug resistance in cancer |
WO2018156989A1 (en) | 2017-02-24 | 2018-08-30 | University Of South Florida | The hsp90 activator aha1 drives production of pathological tau aggregates |
US10272052B2 (en) | 2017-02-24 | 2019-04-30 | University Of South Florida | Compositions and methods for the treatment of tauopathies |
WO2018213320A1 (en) | 2017-05-15 | 2018-11-22 | Duke University | Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents |
WO2019006374A1 (en) | 2017-06-30 | 2019-01-03 | Duke University | Order and disorder as a design principle for stimuli-responsive biopolymer networks |
GB201710973D0 (en) | 2017-07-07 | 2017-08-23 | Avacta Life Sciences Ltd | Scaffold proteins |
US11590345B2 (en) | 2017-08-08 | 2023-02-28 | Pulse Biosciences, Inc. | Treatment of tissue by the application of energy |
US10850095B2 (en) | 2017-08-08 | 2020-12-01 | Pulse Biosciences, Inc. | Treatment of tissue by the application of energy |
US10857347B2 (en) | 2017-09-19 | 2020-12-08 | Pulse Biosciences, Inc. | Treatment instrument and high-voltage connectors for robotic surgical system |
US11607537B2 (en) | 2017-12-05 | 2023-03-21 | Virginia Tech Intellectual Properties, Inc. | Method for treating neurological disorders, including tumors, with electroporation |
AU2019222659B2 (en) | 2018-02-13 | 2024-04-04 | Nanovis, LLC | Inactivating bacteria with electric pulses and antibiotics |
US11311329B2 (en) | 2018-03-13 | 2022-04-26 | Virginia Tech Intellectual Properties, Inc. | Treatment planning for immunotherapy based treatments using non-thermal ablation techniques |
US11925405B2 (en) | 2018-03-13 | 2024-03-12 | Virginia Tech Intellectual Properties, Inc. | Treatment planning system for immunotherapy enhancement via non-thermal ablation |
EP3829622A4 (en) | 2018-08-02 | 2022-05-11 | Duke University | Dual agonist fusion proteins |
US11571569B2 (en) | 2019-02-15 | 2023-02-07 | Pulse Biosciences, Inc. | High-voltage catheters for sub-microsecond pulsing |
US11950835B2 (en) | 2019-06-28 | 2024-04-09 | Virginia Tech Intellectual Properties, Inc. | Cycled pulsing to mitigate thermal damage for multi-electrode irreversible electroporation therapy |
BR102019013578A2 (en) * | 2019-06-28 | 2021-01-05 | Eqt Equipamentos E Tecnologia Ltda. | ELECTROPORATION APPLICATOR TIP FOR ELECTROCHEMOTHERAPY PROCEDURE |
US11512314B2 (en) | 2019-07-12 | 2022-11-29 | Duke University | Amphiphilic polynucleotides |
EP4025144B1 (en) * | 2019-09-02 | 2023-09-06 | Mirai Medical Limited | Electroporation apparatus |
WO2021074695A1 (en) | 2019-10-16 | 2021-04-22 | Avacta Life Sciences Limited | PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES. |
MX2022010460A (en) | 2020-02-25 | 2022-09-19 | Inovio Pharmaceuticals Inc | Vaccines against coronavirus and methods of use. |
IL297903A (en) | 2020-05-14 | 2023-01-01 | Inovio Pharmaceuticals Inc | Vaccines for recurrent respiratory papillomatosis and methods of using the same |
GB202101299D0 (en) | 2020-06-09 | 2021-03-17 | Avacta Life Sciences Ltd | Diagnostic polypetides and methods |
EP4165183A1 (en) | 2020-06-12 | 2023-04-19 | University of Rochester | Encoding and expression of ace-trnas |
WO2022234003A1 (en) | 2021-05-07 | 2022-11-10 | Avacta Life Sciences Limited | Cd33 binding polypeptides with stefin a protein |
WO2023057946A1 (en) | 2021-10-07 | 2023-04-13 | Avacta Life Sciences Limited | Serum half-life extended pd-l1 binding polypeptides |
WO2023057567A1 (en) | 2021-10-07 | 2023-04-13 | Avacta Life Sciences Limited | Pd-l1 binding affimers |
WO2023150753A1 (en) | 2022-02-07 | 2023-08-10 | University Of Rochester | Optimized sequences for enhanced trna expression or/and nonsense mutation suppression |
Citations (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1099062A (en) * | 1913-12-10 | 1914-06-02 | Peter P Laposkey | Electric scalp appliance. |
US3773051A (en) * | 1972-03-01 | 1973-11-20 | Research Corp | Method and apparatus for stimulation of body tissue |
US4116238A (en) * | 1976-08-18 | 1978-09-26 | Midgard Electronics Company, Inc. | High voltage constant current source for iontophoresis |
US4528265A (en) * | 1982-05-11 | 1985-07-09 | Becker Robert O | Processes and products involving cell modification |
US4784757A (en) * | 1987-07-13 | 1988-11-15 | Nelson Edgar E | Solid material separator |
US4955378A (en) * | 1988-05-02 | 1990-09-11 | University Of South Florida | Apparatus and methods for performing electrofusion at specific anatomical sites |
US5019034A (en) * | 1988-01-21 | 1991-05-28 | Massachusetts Institute Of Technology | Control of transport of molecules across tissue using electroporation |
US5036850A (en) * | 1989-08-25 | 1991-08-06 | Staodyn, Inc. | Biphasic pulse output stage for electronic stimulating device |
US5058605A (en) * | 1989-02-22 | 1991-10-22 | Ceske Vysoke Uceni Technicke | Method and device for the controlled local, non-invasive application of dc pulses to human and animal tissues |
US5097833A (en) * | 1989-09-19 | 1992-03-24 | Campos James M | Transcutaneous electrical nerve and/or muscle stimulator |
US5128257A (en) * | 1987-08-31 | 1992-07-07 | Baer Bradford W | Electroporation apparatus and process |
US5137817A (en) * | 1990-10-05 | 1992-08-11 | Amoco Corporation | Apparatus and method for electroporation |
US5273525A (en) * | 1992-08-13 | 1993-12-28 | Btx Inc. | Injection and electroporation apparatus for drug and gene delivery |
US5318514A (en) * | 1992-08-17 | 1994-06-07 | Btx, Inc. | Applicator for the electroporation of drugs and genes into surface cells |
US5389069A (en) * | 1988-01-21 | 1995-02-14 | Massachusetts Institute Of Technology | Method and apparatus for in vivo electroporation of remote cells and tissue |
US5411525A (en) * | 1992-01-30 | 1995-05-02 | Cardiac Pacemakers, Inc. | Dual capacitor biphasic defibrillator waveform generator employing selective connection of capacitors for each phase |
US5439440A (en) * | 1993-04-01 | 1995-08-08 | Genetronics, Inc. | Electroporation system with voltage control feedback for clinical applications |
US5468223A (en) * | 1992-11-30 | 1995-11-21 | C.N.R.S. Paris | Electrochemotherapy |
US5507781A (en) * | 1991-05-23 | 1996-04-16 | Angeion Corporation | Implantable defibrillator system with capacitor switching circuitry |
US5674267A (en) * | 1993-03-30 | 1997-10-07 | Centre National De La Recherche Scientifique | Electric pulse applicator using pairs of needle electrodes for the treatment of biological tissue |
US5688233A (en) * | 1992-08-17 | 1997-11-18 | Genetronics, Inc. | Electronincorporation enhanced transdermal delivery of molecules |
US5702359A (en) * | 1995-06-06 | 1997-12-30 | Genetronics, Inc. | Needle electrodes for mediated delivery of drugs and genes |
US5873849A (en) * | 1997-04-24 | 1999-02-23 | Ichor Medical Systems, Inc. | Electrodes and electrode arrays for generating electroporation inducing electrical fields |
US5993434A (en) * | 1993-04-01 | 1999-11-30 | Genetronics, Inc. | Method of treatment using electroporation mediated delivery of drugs and genes |
US6009347A (en) * | 1998-01-27 | 1999-12-28 | Genetronics, Inc. | Electroporation apparatus with connective electrode template |
US6041252A (en) * | 1995-06-07 | 2000-03-21 | Ichor Medical Systems Inc. | Drug delivery system and method |
US6110161A (en) * | 1997-04-03 | 2000-08-29 | Electrofect As | Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle |
US6261281B1 (en) * | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989010690A1 (en) * | 1988-05-02 | 1989-11-16 | University Of South Florida | Method for electrofusing biological particles to tissues |
-
1995
- 1995-06-06 US US08/467,566 patent/US5702359A/en not_active Expired - Lifetime
-
1996
- 1996-05-22 RU RU98100256/14A patent/RU2168337C2/en active
-
2004
- 2004-02-20 US US10/783,161 patent/US20050192542A1/en not_active Abandoned
Patent Citations (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1099062A (en) * | 1913-12-10 | 1914-06-02 | Peter P Laposkey | Electric scalp appliance. |
US3773051A (en) * | 1972-03-01 | 1973-11-20 | Research Corp | Method and apparatus for stimulation of body tissue |
US4116238A (en) * | 1976-08-18 | 1978-09-26 | Midgard Electronics Company, Inc. | High voltage constant current source for iontophoresis |
US4528265A (en) * | 1982-05-11 | 1985-07-09 | Becker Robert O | Processes and products involving cell modification |
US4784757A (en) * | 1987-07-13 | 1988-11-15 | Nelson Edgar E | Solid material separator |
US5128257A (en) * | 1987-08-31 | 1992-07-07 | Baer Bradford W | Electroporation apparatus and process |
US5019034B1 (en) * | 1988-01-21 | 1995-08-15 | Massachusetts Inst Technology | Control of transport of molecules across tissue using electroporation |
US5019034A (en) * | 1988-01-21 | 1991-05-28 | Massachusetts Institute Of Technology | Control of transport of molecules across tissue using electroporation |
US5389069A (en) * | 1988-01-21 | 1995-02-14 | Massachusetts Institute Of Technology | Method and apparatus for in vivo electroporation of remote cells and tissue |
US4955378A (en) * | 1988-05-02 | 1990-09-11 | University Of South Florida | Apparatus and methods for performing electrofusion at specific anatomical sites |
US5058605A (en) * | 1989-02-22 | 1991-10-22 | Ceske Vysoke Uceni Technicke | Method and device for the controlled local, non-invasive application of dc pulses to human and animal tissues |
US5036850A (en) * | 1989-08-25 | 1991-08-06 | Staodyn, Inc. | Biphasic pulse output stage for electronic stimulating device |
US5097833A (en) * | 1989-09-19 | 1992-03-24 | Campos James M | Transcutaneous electrical nerve and/or muscle stimulator |
US5137817A (en) * | 1990-10-05 | 1992-08-11 | Amoco Corporation | Apparatus and method for electroporation |
US5507781A (en) * | 1991-05-23 | 1996-04-16 | Angeion Corporation | Implantable defibrillator system with capacitor switching circuitry |
US5411525A (en) * | 1992-01-30 | 1995-05-02 | Cardiac Pacemakers, Inc. | Dual capacitor biphasic defibrillator waveform generator employing selective connection of capacitors for each phase |
US5273525A (en) * | 1992-08-13 | 1993-12-28 | Btx Inc. | Injection and electroporation apparatus for drug and gene delivery |
US5318514A (en) * | 1992-08-17 | 1994-06-07 | Btx, Inc. | Applicator for the electroporation of drugs and genes into surface cells |
US5688233A (en) * | 1992-08-17 | 1997-11-18 | Genetronics, Inc. | Electronincorporation enhanced transdermal delivery of molecules |
US5468223A (en) * | 1992-11-30 | 1995-11-21 | C.N.R.S. Paris | Electrochemotherapy |
US5674267A (en) * | 1993-03-30 | 1997-10-07 | Centre National De La Recherche Scientifique | Electric pulse applicator using pairs of needle electrodes for the treatment of biological tissue |
US5439440A (en) * | 1993-04-01 | 1995-08-08 | Genetronics, Inc. | Electroporation system with voltage control feedback for clinical applications |
US5993434A (en) * | 1993-04-01 | 1999-11-30 | Genetronics, Inc. | Method of treatment using electroporation mediated delivery of drugs and genes |
US6451002B1 (en) * | 1993-04-01 | 2002-09-17 | Genetronics, Inc. | Method of treatment using electroporation mediated delivery of drugs and genes |
US6569149B2 (en) * | 1993-04-01 | 2003-05-27 | Genetronics, Inc. | Method of treatment using electroporation mediated delivery of drugs and genes |
US5702359A (en) * | 1995-06-06 | 1997-12-30 | Genetronics, Inc. | Needle electrodes for mediated delivery of drugs and genes |
US6041252A (en) * | 1995-06-07 | 2000-03-21 | Ichor Medical Systems Inc. | Drug delivery system and method |
US6110161A (en) * | 1997-04-03 | 2000-08-29 | Electrofect As | Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle |
US6261281B1 (en) * | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
US5873849A (en) * | 1997-04-24 | 1999-02-23 | Ichor Medical Systems, Inc. | Electrodes and electrode arrays for generating electroporation inducing electrical fields |
US6278895B1 (en) * | 1997-04-24 | 2001-08-21 | Ichor Medical Systems, Inc. | Electrodes and electrode arrays for generating electroporation inducing electrical fields |
US6009347A (en) * | 1998-01-27 | 1999-12-28 | Genetronics, Inc. | Electroporation apparatus with connective electrode template |
Cited By (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9186514B2 (en) | 1996-01-08 | 2015-11-17 | Impulse Dynamics Nv | Electrical muscle controller |
US8311629B2 (en) | 1996-01-08 | 2012-11-13 | Impulse Dynamics, N.V. | Electrical muscle controller |
US9289618B1 (en) | 1996-01-08 | 2016-03-22 | Impulse Dynamics Nv | Electrical muscle controller |
US8958872B2 (en) | 1996-01-08 | 2015-02-17 | Impulse Dynamics, N.V. | Electrical muscle controller |
US8825152B2 (en) | 1996-01-08 | 2014-09-02 | Impulse Dynamics, N.V. | Modulation of intracellular calcium concentration using non-excitatory electrical signals applied to the tissue |
US8655444B2 (en) | 1996-01-08 | 2014-02-18 | Impulse Dynamics, N.V. | Electrical muscle controller |
US8321013B2 (en) | 1996-01-08 | 2012-11-27 | Impulse Dynamics, N.V. | Electrical muscle controller and pacing with hemodynamic enhancement |
US8260416B2 (en) | 1996-01-08 | 2012-09-04 | Impulse Dynamics, N.V. | Electrical muscle controller |
US8301247B2 (en) | 1996-01-08 | 2012-10-30 | Impulse Dynamics, N.V. | Electrical muscle controller |
US8306616B2 (en) | 1996-01-08 | 2012-11-06 | Impulse Dynamics, N.V. | Electrical muscle controller |
US8306617B2 (en) | 1996-01-08 | 2012-11-06 | Impulse Dynamics N.V. | Electrical muscle controller |
US9713723B2 (en) | 1996-01-11 | 2017-07-25 | Impulse Dynamics Nv | Signal delivery through the right ventricular septum |
US7966071B2 (en) | 1997-07-16 | 2011-06-21 | Metacure Limited | Method and apparatus for regulating glucose level |
US8805507B2 (en) | 1997-07-16 | 2014-08-12 | Metacure Limited | Methods for controlling labor and treating menstrual cramps in uterine muscle |
US8219201B2 (en) | 1997-07-16 | 2012-07-10 | Metacure Limited | Smooth muscle controller for controlling the level of a chemical in the blood stream |
US20070185540A1 (en) * | 1997-07-16 | 2007-08-09 | Shlomo Ben-Haim | Smooth Muscle Controller |
US9265930B2 (en) | 1997-07-16 | 2016-02-23 | Metacure Limited | Methods and devices for modifying vascular parameters |
US8700161B2 (en) | 1999-03-05 | 2014-04-15 | Metacure Limited | Blood glucose level control |
US9101765B2 (en) | 1999-03-05 | 2015-08-11 | Metacure Limited | Non-immediate effects of therapy |
US8666495B2 (en) | 1999-03-05 | 2014-03-04 | Metacure Limited | Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar |
US7190997B1 (en) * | 1999-06-04 | 2007-03-13 | Impulse Dynamics Nv | Drug delivery device |
US11439815B2 (en) | 2003-03-10 | 2022-09-13 | Impulse Dynamics Nv | Protein activity modification |
US7840262B2 (en) | 2003-03-10 | 2010-11-23 | Impulse Dynamics Nv | Apparatus and method for delivering electrical signals to modify gene expression in cardiac tissue |
US8326416B2 (en) | 2003-03-10 | 2012-12-04 | Impulse Dynamics Nv | Apparatus and method for delivering electrical signals to modify gene expression in cardiac tissue |
US9931503B2 (en) | 2003-03-10 | 2018-04-03 | Impulse Dynamics Nv | Protein activity modification |
US8792985B2 (en) | 2003-07-21 | 2014-07-29 | Metacure Limited | Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar |
US8977353B2 (en) | 2004-03-10 | 2015-03-10 | Impulse Dynamics Nv | Protein activity modification |
US9440080B2 (en) | 2004-03-10 | 2016-09-13 | Impulse Dynamics Nv | Protein activity modification |
US11779768B2 (en) | 2004-03-10 | 2023-10-10 | Impulse Dynamics Nv | Protein activity modification |
US10352948B2 (en) | 2004-03-10 | 2019-07-16 | Impulse Dynamics Nv | Protein activity modification |
US8548583B2 (en) | 2004-03-10 | 2013-10-01 | Impulse Dynamics Nv | Protein activity modification |
US8352031B2 (en) | 2004-03-10 | 2013-01-08 | Impulse Dynamics Nv | Protein activity modification |
US8244371B2 (en) | 2005-03-18 | 2012-08-14 | Metacure Limited | Pancreas lead |
US9014800B2 (en) | 2006-04-07 | 2015-04-21 | University Of South Florida | Passive electric field focus system for in vivo and in vitro applications |
US20090131994A1 (en) * | 2006-04-07 | 2009-05-21 | University Of South Florida | Passive Electric Field Focus System for In Vivo and In Vitro Applications |
US9486626B2 (en) | 2006-04-07 | 2016-11-08 | University Of South Florida | Passive electric field focus system for in vivo and in vitro applications |
US8934975B2 (en) | 2010-02-01 | 2015-01-13 | Metacure Limited | Gastrointestinal electrical therapy |
US9457183B2 (en) | 2011-06-15 | 2016-10-04 | Tripep Ab | Injection needle and device |
WO2023224829A1 (en) * | 2022-05-16 | 2023-11-23 | Vector Surgical, Llc | Intracellular treatment device and methods of use thereof |
Also Published As
Publication number | Publication date |
---|---|
RU2168337C2 (en) | 2001-06-10 |
US5702359A (en) | 1997-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6763264B2 (en) | Method of treatment using electroporation mediated delivery of drugs and genes | |
US20050192542A1 (en) | Method of treatment using electroporation mediated delivery of drugs and genes | |
CA2268026C (en) | Method and apparatus for using electroporation mediated delivery of drugs and genes | |
US6241701B1 (en) | Apparatus for electroporation mediated delivery of drugs and genes | |
US6216034B1 (en) | Method of programming an array of needle electrodes for electroporation therapy of tissue | |
US6520950B1 (en) | Method of electroporation-enhanced delivery of active agents | |
US20040204669A1 (en) | Apparatus for electroporation mediated delivery for drugs and genes | |
MXPA97008316A (en) | Method of treatment using administration of drugs and genes through electroporac |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE |